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ABSTRACT 
Nursing homes are an essential yet understudied provider of cancer-related care 
for those with complex health needs. Nine percent of nursing home residents have a 
cancer diagnosis at admission, and it is estimated that one-third of them experience pain 
on a daily basis. Although pain management is an essential component of disease 
treatment, few studies have evaluated analgesic medication use among adults with cancer 
in this setting. Use of opioids, which are the mainstay of pain management in older adults 
because of their effectiveness in controlling moderate to severe pain, may be significantly 
related to coverage by the Medicare Part D prescription drug benefit. However, little is 
known about Medicare Part D’s effects on opioid use in this patient population. A limited 
body of evidence also suggests that despite known risks of overdose and respiratory 
depression in opioid-naïve patients treated with long-acting opioids, use of these agents 
may be common in nursing homes.  
This dissertation examined access to appropriate and effective pain-related health 
care services among US nursing home residents, with a special focus on those with 
cancer. Objectives of this dissertation were to: 1) estimate the prevalence, and identify 
resident-level correlates, of pain and receipt of analgesic medications; 2) use a quasi-
experimental research design to examine the relationship between implementation of 
Medicare Part D and changes in the use of fentanyl patches and other opioids; and 3) to 
estimate the prevalence, and identify resident-level correlates, of naïve initiation of long-
acting opioids. Data on residents’ health status from the Resident Assessment 
Instrument/Minimum Data Set (versions 2.0 and 3.0) were linked with prescription drug 
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transaction data from a nationwide long-term care pharmacy (January 2005–June 2007) 
and the Centers for Medicare and Medicaid Services (January–December 2011).    
From 2006 to 2007, more than 65% of residents of nursing homes throughout the 
US with cancer experienced pain (28.3% on a daily basis), among whom 13.5% reported 
severe pain. More than 17% of these residents who experienced daily pain received no 
analgesics (95% confidence interval [CI]: 16.0–19.1%), and treatment was negatively 
associated among those with advanced age, cognitive impairment, feeding tubes, and 
restraints. These findings coincided with changing patterns in opioid use among residents 
with cancer, including relatively abrupt 10% and 21% decreases in use of fentanyl 
patches and other strong opioids, respectively, after the 2006 implementation of Medicare 
Part D. In the years since Medicare Part D was introduced, some treatment practices in 
nursing homes have not been concordant with clinical guidelines for pain management 
among older adults. Among a contemporary population of long-stay nursing home 
residents with and without cancer, 10.0% (95% CI: 9.4–10.6%) of those who began 
receiving a long-acting opioid after nursing home admission had not previously received 
opioid therapy. Odds of naïve initiation of these potent opioids were increased among 
residents with terminal prognosis, functional impairment, feeding tubes, and cancer.       
This dissertation provides new evidence on pharmaceutical management of pain 
and on Medicare Part D’s impact on opioid use in nursing home residents. Results from 
this dissertation shed light on nursing home residents’ access to pain-related health care 
services and provide initial directions for targeted efforts to improve the quality of pain 
treatment in nursing homes.  
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CHAPTER I:  
INTRODUCTION 
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1.1 Specific Aims 
 Approximately 1.6 million Americans are expected to be diagnosed with cancer in 
2015,1 with more than half of these new diagnoses of cancer  occurring among adults 
aged 65 years.2 As the provision of continuing care for older adults has shifted away 
from the hospital setting, nursing homes have become an essential yet understudied 
provider of cancer care for those with complex health needs.3 Of an estimated 1.4 million 
nursing home residents,4 nearly 9% have an active cancer diagnosis at admission.5 Pain, 
one of the most common side effects of cancer, is experienced on a daily basis by 
upwards of one-third of nursing home residents with cancer.6 Although management of 
cancer-related pain is an essential component of disease treatment, more than one-quarter 
of nursing home residents with severe pain may not receive any analgesics.6 A limited 
number of studies have estimated the prevalence of cancer-related pain in nursing 
homes,3,6 but few have characterized its pharmacologic treatment.  
 Opioids are the mainstay of cancer-related pain management among older adults 
because of their effectiveness in controlling moderate to severe pain.7,8 Clinical 
guidelines recommend a sequential approach from the use of oral non-opioids for mild 
pain to the use of opioids for persons with more intense pain.9,10 Longitudinal studies that 
describe patterns of opioid use among nursing home residents with cancer are lacking.  
 Opioid use in nursing home residents may be significantly related to coverage by 
the Medicare Part D prescription drug benefit that was implemented on January 1, 2006, 
and replaced Medicaid as the primary source of prescription drug coverage in nursing 
homes. Although Medicare Part D was created to improve Medicare beneficiaries’ access 
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to essential medications, it may have had unintended consequences for nursing home 
residents who suffer from cancer-related pain. Prescription drug plans that privately 
administer Medicare Part D are required to cover “all or substantially all” medications in 
six classes commonly used by older adults;11 however, broad coverage of opioids is not 
required even though they are the most commonly used analgesics in nursing homes.12 
Long-term care pharmacy claims for opioids are among the most frequently rejected by 
Medicare Part D plans, with rejections for administrative reasons increasing from 16% in 
2007 to 28% in 2010.13 Limited evidence exists on Medicare Part D’s effects on opioid 
use among nursing home residents with cancer.  
 This dissertation examined access to appropriate and effective pain-related health 
care services among adults with cancer and a more general population of older adults 
who resided in US nursing homes. The specific aims of this dissertation were as follows:  
 Aim 1. We estimated the prevalence and resident-level correlates of pain and 
analgesic medication receipt among nursing home residents with cancer.  
 Aim 2. We used a quasi-experimental research design to examine the extent to 
which the implementation of Medicare Part D was associated with changes in fentanyl 
patch and other opioid use among nursing home residents with cancer. 
 Hypothesis: There would be a reduction in fentanyl patch use after the January 1, 
2006, implementation of Medicare Part D. 
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Aim 3. We evaluated the prevalence and resident-level correlates of naïve opioid 
initiation in nursing home residents who receive a long-acting opioid within 30 days of 
nursing home admission.  
1.2 Background and Significance 
1.2.1  Cancer and Cancer-Related Pain in Older Adults 
 Adults aged 65 years and older represented 14.1% of the US population in 2013,14 
and this estimate is expected to increase to 19.3% by 2030.15 Approximately 1.6 million 
Americans are expected to be diagnosed with cancer in 2015, with 78% of new diagnoses 
occurring among adults aged 55 years.1 Cancer is the second leading cause of death in 
adults aged 65 years, accounting for approximately 403,000 deaths in older adults in 
2012.16 
 Pain is the most common symptom of cancer in older adults.17,18 More than half 
of individuals with cancer experience pain, regardless of cancer type, and more than one-
third rate their pain as moderate or severe.19 Pain is prevalent across the continuum of 
cancer care: 59% of individuals undergoing active treatment, 33% of those whose cancer 
is in remission, and 64% of those with metastatic, advanced or terminal disease 
experience pain.19 Inadequately-treated pain has numerous psychological and 
physiological consequences, including depression, anxiety, sleep disturbance, decreased 
socialization, and impaired mobility.20–22  
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1.2.2 Opioid Use for Cancer-Related Pain Management 
 Opioid analgesics are highly effective in controlling moderate to severe pain and 
are the mainstay of cancer-related pain management among older adults.7,8 Opioids are 
central to established clinical practice guidelines for adult cancer pain management, 
including those published by the World Health Organization (WHO)9 and the National 
Comprehensive Cancer Network, an alliance of 21 National Cancer Institute-designated 
cancer centers.10 These guidelines recommend a sequential analgesic therapy 
intensification approach from the use of non-opioids for mild pain to the use of opioids 
for more intense pain.9,10 Duration of analgesic effect should also be carefully considered 
to prevent inadvertent overdose, with use of short-acting opioids advised for patients who 
are not chronically receiving opioid therapy and, therefore, have not developed 
significant tolerance to side effects (e.g., drowsiness, respiratory depression).10,23 Use of 
the clinical practice guidelines is 80-90% effective at managing cancer-related pain 
overall.9,24,25 
1.2.3 Pain Management in Nursing Homes 
 As the provision of continuing care for older adults has shifted away from acute 
care settings, nursing homes have become essential providers of cancer care.3 Of an 
estimated 1.4 million nursing home residents,4 nearly 9% have an active cancer diagnosis 
at admission.5 Nursing homes are expected to carry more of the burden of cancer care 
delivery, given a 40% lifetime risk of nursing home placement after age 65 years,26–28 
rising prevalence of cancer among a growing older adult population, and improvements 
in life expectancy after a cancer diagnosis.29 Approximately 31.3% of Medicare 
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beneficiaries with cancer receive nursing home care in the last 90 days before death, and 
17.1% die in the nursing home.30 An estimated 29.4% of nursing home residents with 
cancer experience pain on a daily basis.6       
 Despite this finding, a limited number of studies have critically evaluated patterns 
and correlates of analgesic use in nursing home residents. Rigler and colleagues 
documented that use of long-acting opioids is more common among nursing home 
residents than older adults living in the community.31 Data describing analgesic use in 
nursing home residents suggest that opioids are the most commonly used class (67.6% 
compared to 24.8% for non-steroidal anti-inflammatory drugs).12 Yet, how opioids are 
used may not be guideline concordant. Dosa and colleagues estimated that 39.3% of 
nursing home residents (10.8% of whom had cancer) who received a long-acting opioid 
were previously opioid-naïve, despite Food and Drug Administration (FDA) public 
health advisory warnings of morbidity and death associated with initiation of these potent 
agents in new opioid users.32 Naïve initiation of long-acting opioids was more frequent 
among nursing home residents with advanced age and increased cognitive impairment. 
Data specifically describing analgesic use among patients with cancer in nursing homes 
are scant. The most comprehensive study to date (published in 1998) found that among 
nearly 14,000 nursing home residents with cancer, 26% of those with daily cancer pain 
did not receive any analgesics.6 Advanced age, minority race, increasing numbers of 
other medication6 and low cognitive performance6,33,34 were associated with failure to 
receive analgesics, even at the end of life.33,34  
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1.2.4 Impact of Medicare Part D on Opioid Use for Cancer-Related Pain 
Management 
 Medicare Part D, the Medicare prescription drug benefit, may have influenced 
opioid use in nursing homes. Implemented on January 1, 2006, Medicare Part D replaced 
Medicaid as the primary source of prescription drug coverage in nursing homes. An 
estimated 63% of nursing home residents who were dually eligible for Medicaid and 
Medicare were automatically enrolled in Medicare Part D,35 and another one-third of 
Medicare-only residents voluntarily enrolled. Medicare Part D prescription drug plans are 
not required to cover opioids, owing to concerns about inappropriate use among 
Medicare beneficiaries.36 Long-term care pharmacy claims for opioids are among the 
most frequently rejected by Medicare Part D plans, with rejections for administrative 
reasons increasing from 16% in 2007 to 28% in 2010.13 Although Medicare Part D was 
created to improve access to essential medication, it may have had unintended 
consequences for those who suffer from cancer-related pain.  
 Evidence of Medicare Part D’s impact on opioid use in nursing homes is limited 
but suggestive of barriers to opioids for cancer-related pain management. Long-term care 
pharmacy claims for generic fentanyl and hydrocodone-acetaminophen combinations 
were among the most frequently rejected by Medicare Part D prescription drug plans in 
2006.37 Generic opioids remained among the most commonly rejected prescription drugs 
in 2010, with rejections of nearly one-third of claims for oxycodone, oxycodone-
acetaminophen combinations, extended-release morphine sulfate, and transdermal 
fentanyl systems.13 There is evidence of relationships between Medicare Part D and 
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decreased use of medications that carry safety concerns when used to treat older adults.38 
There have not been any studies of Medicare Part D’s impact on both opioid use and 
cancer patients residing in nursing homes.  
1.3 Research Design and Methods 
1.3.1 Data Sources 
Aims 1 and 2 
 A nationwide long-term care pharmacy provided data for Aims 1 and 2 under a 
data use agreement. Data included nursing home resident health assessments from the 
Resident Assessment Instrument/Minimum Data Set (MDS) version 2.0 linked with all-
payer administrative records of all dispensed prescription and over-the-counter 
medication.  
 MDS 2.0 is a systematic and comprehensive assessment of care planning and 
resident health that consists of more than 400 items, including sociodemographic 
information, clinical characteristics (e.g., cognitive patterns, communication, mood and 
behavior, signs, symptoms), active clinical diagnoses, and treatments provided.39,40 It 
includes multi-item summary scales for measures of functional status (Activities of Daily 
Living [ADL] Hierarchy Scale),41 depressed mood (Depression Rating Scale),42 and 
cognitive status (Cognitive Performance Scale).43 Long-term care facilities that 
participate in the Medicare and Medicaid programs (approximately 96% of all US 
facilities) are required to perform full MDS assessments on residents at admission and 
annually; a subset of the MDS items are assessed quarterly or when a resident 
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experiences a significant change in health status.39 A registered nurse performs the 
assessment of a resident’s status over the previous seven days based on medical record 
review, direct observation of and communication with the resident, family interviews, 
and discussions with the resident’s medical and direct care teams.  
 The long-term care pharmacy linked the MDS assessments to drug dispensing 
records using unique study identifiers. Drug data came from more than 2.5 million 
residents of approximately 16,000 nursing homes across 48 states. The drug dispensing 
records were of all medications dispensed to nursing home residents from January 1, 
2005, to June 30, 2007. Data elements included brand and generic names, product 
identification code (National Drug Code [NDC]), prescription date, days’ supply, 
quantity dispensed, and payment source (i.e., cash, Medicaid, private insurance, Medicare 
Parts A/B, Medicare Part D, and facility/hospice). Resident-level information included 
age, sex, and state of nursing home residence.  
Aim 3 
The Centers for Medicare and Medicaid Services (CMS) provided data for Aim 3 
under Data Use Agreement 26885. Data included: 1) nursing home resident health 
assessments from the Resident Assessment Instrument/MDS version 3.0, 2) Master 
Beneficiary Summary Files that determine Medicare enrollment, 3) MedPar files 
containing hospital claims data, and 4) Medicare Part D prescription drug transaction 
data.   
10 
 
MDS 3.0 is a revision of MDS 2.0 and was implemented in all Medicare- and 
Medicaid-certified nursing homes in October 2010. It is a systematic and comprehensive 
assessment of care planning and resident health that consists of sociodemographic 
information; clinical items (e.g., falls and balance, bladder and bowel, communication, 
behavior, signs, symptoms); active diagnoses; and treatments, procedures, and 
programs.44,45 MDS 3.0 multi-item summary scales exist for measurement of functional 
status (Resource Utilization Groups-III ADL)46 and cognitive status (Cognitive Function 
Scale).47 As in MDS 2.0, nursing home providers are required to perform full MDS 
assessments on residents at admission and annually, and a subset of the MDS items are 
assessed quarterly or when a resident experiences a significant change in health status.44 
The most significant conceptual departure from MDS 2.0 is the inclusion of direct 
resident interviews to assess key domains of health. Although resident interviews are the 
preferred method for completing the assessment, nursing home staff may answer 
alternative observation items on behalf of residents who cannot make themselves 
understood at least some of the time or who cannot complete an interview. Family 
members or significant others may answer items regarding resident preferences.  
CMS provided a unique study identifier to link the MDS assessments to Medicare 
Part D prescription drug transactions (i.e., event and characteristics files). The 
transactions were for all Medicare Part D-reimbursed prescription medications dispensed 
to nursing home residents from January 1, 2011, to December 31, 2011. Data elements in 
the event file included product identification code (NDC), service date, days’ supply, and 
quantity dispensed. Data elements from the characteristics file included brand and generic 
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names, drug strength, and drug formulation, and the Multum drug database was used to 
map drug names to therapeutic categories. Beneficiary-level information included dates 
of Medicare Part D enrollment and death.   
1.3.2 Study Designs and Populations 
Aim 1 
We conducted a cross-sectional study for this study aim. Figure 1-1 shows the 
sample selection strategy. The sampling frame consisted of nursing home residents with 
MDS assessments performed between February 1, 2006, and June 30, 2007 (n = 
166,139). We included in our sample nursing home residents with a cancer diagnosis 
indicated on MDS assessment (n = 23,485). A cancer diagnosis was indicated by a check 
box under MDS “Section I. Disease Diagnoses” and reported only if the diagnosis was 
related to “current ADL status, cognitive status, mood and behavior status, medical 
treatments, nursing monitoring, or risk of death” and not inactive.39  
We excluded nursing home residents admitted to the nursing home before 
February 1, 2006 (n = 13,452). Newly-admitted residents were those who had an MDS 
assessment performed at admission (i.e., by day 14). We also excluded nursing home 
residents whose prescriptions could not be identified using NDCs (n = 1,633) and who 
were not eligible for Medicare (n = 25). Medicare-eligibility was indicated by age 65 
years or, for younger nursing home residents, receipt of 1 Medicare-paid prescription 
drug. Finally, we excluded nursing home residents who were comatose (n = 7) and who 
were missing information on key sociodemographic and clinical characteristics (n = 274).  
12 
 
The final sample size was 8,094 nursing home residents who were admitted to 
1,382 nursing homes throughout the US.   
Aim 2 
 
We conducted a segmented Poisson regression of interrupted time-series. Figure 
1-2 shows the sample selection strategy. The sampling frame consisted of nursing home 
residents with MDS assessments performed between January 1, 2005, and June 30, 2007 
(n = 234,308). We included in our sample nursing home residents with a cancer diagnosis 
indicated on MDS assessment (n = 23,485). A cancer diagnosis was indicated by a check 
box under MDS “Section I. Disease Diagnoses” and reported only if the diagnosis was 
related to “current ADL status, cognitive status, mood and behavior status, medical 
treatments, nursing monitoring, or risk of death” and not inactive.39  
 We excluded residents who were not eligible for Medicare at any point during the 
study (n = 1,320). Medicare-eligibility was indicated by age 65 years or, for younger 
nursing home residents, receipt of 1 Medicare-paid prescription drug. We also excluded 
residents who resided in facilities that lacked pharmacy dispensing records in both pre- 
and post-Medicare Part D periods (n = 2,383) and who were missing information on key 
sociodemographic and clinical characteristics (n = 1,183).  
 The final sample size was 18,599 nursing home residents who were admitted to 
1,112 nursing homes.   
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Aim 3 
 We conducted a cross-sectional study for this study aim. Figure 1-3 shows the 
sample selection strategy. The sampling frame consisted of Medicare-enrolled nursing 
home residents with an admission assessment performed between January 1, 2011, and 
December 31, 2011 (n = 3,273,636). We required that residents have a nursing home stay 
90 days (n = 1,103,195), as Medicare Part D prescription drug transactions may not 
include medications associated with skilled nursing facility care covered by Medicare 
Part A. We excluded residents who were comatose (n = 3,479); who were admitted to the 
nursing home between January 1, 2011, and March 31, 2011 (n = 130,598); who did not 
initiate a long-acting opioid after nursing home admission (n = 949,965); who did not 
have three months of continuous enrollment in Medicare Part D prior to initiation of a 
long-acting opioid in the nursing home (n = 1,176); who had a hospital admission in the 
seven days prior to initiation of a long-acting opioid in the nursing home (n = 874); or 
who were missing information on key sociodemographic or clinical characteristics (n = 
1,041). We identified 16,062 nursing home residents who met these eligibility criteria. 
Although we estimated the proportion of residents naively initiating a long-acting opioid 
using several subsamples derived from this population, the primary analysis was 
conducted in 9,543 residents who were admitted to 3,018 facilities and who initiated a 
long-acting opioid in the first 30 days of admission.  
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1.3.3 Measures 
Outcome Variables (Aim 1) 
Pain. MDS 2.0 defines pain as any type of physical pain or discomfort in any part of the 
body occurring daily over the seven days preceding the assessment. It includes one item 
for frequency of pain, rated as no pain, less than daily, and daily, and one item for pain 
intensity, rated as mild, moderate, or horrible/excruciating. The MDS instructions for 
these measures recommend reliance on resident self-report whenever possible, although 
family and staff observations may also be used. The reliability of these items exceeds 
intraclass correlation of 0.7048 and a summary scale based on these items has been 
validated with the vertical Visual Analog Scale.  
Analgesic use. The long-term care pharmacy that provided data for Aim 1 also furnished 
a drug dictionary that we used to translate NDCs from the drug dispensing records into 
therapeutic classes and sub-classes. Analgesics are listed in Table 1-1 and were classified 
as non-opioids, mild opioids, and strong opioids according to the WHO “ladder” for 
cancer pain relief;9,24,25 by formulation (e.g., oral, intravenous/intramuscular, transdermal, 
suppository); and by duration of effect (i.e., short-acting, long-acting).  
Outcome Variables (Aim 2) 
Opioid use: We created four categories of analgesics: 1) all opioids typically used to treat 
moderate to severe pain (WHO level 3 drugs); 2) fentanyl patches; 3) potential fentanyl 
patch substitutes (i.e., other WHO level 3 drugs); and 4) opioids used for mild to 
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moderate pain (WHO level 2 drugs). Fentanyl patches included branded and generic 
medications. Other WHO level 3 drugs included oral and injectable formulations of 
fentanyl, morphine, hydromorphone, oxycodone, oxymorphone, methadone, 
buprenorphine, and meperidine.49 WHO level 2 drugs included codeine, hydrocodone, 
propoxyphene, pentazocine, butorphanol, standardized opium, tramadol, and any 
combination of these drugs with non-steroidal anti-inflammatory drugs and 
acetaminophen.49 For each of the four categories of analgesics, we created two outcome 
measures: 1) monthly proportion of nursing home residents receiving 1 prescription of 
interest and 2) monthly proportion of resident-therapy days covered. Outcomes were 
examined from January 2005 through December 2005 (pre-Medicare Part D 
implementation) and from February 2006 through June 2007 (post-Medicare Part D 
implementation).  
Outcome Variables (Aim 3) 
Naïve initiation of long-acting opioid. We categorized opioid analgesics by duration of 
effect (i.e., long-acting, short-acting) according to recent clinical practice guidelines that 
consider pain management by level of opioid-tolerance.10,50,51 Long-acting opioids 
included controlled- or extended-release formulations of hydromorphone, morphine 
sulfate, oxycodone, oxymorphone, and tramadol, as well as any dose of fentanyl patch 
and buprenorphine patch. Brand and generic names are listed in Table 1-1. Short-acting 
opioids included immediate-release formulations of buprenorphine, butorphanol, codeine, 
fentanyl, hydrocodone, hydromorphone, meperidine, morphine sulfate, nalbuphine, 
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opium, oxymorphone, oxycodone, pentazocine, tapentadol, and tramadol. Opioids 
combined with acetaminophen or non-steroidal anti-inflammatory drugs, which limit the 
maximum daily dose because of risks of liver and gastrointestinal toxicity, were also 
considered short-acting.52  
 We evaluated the first 30 days of a nursing home stay based on the expectation 
that initial provision of analgesic medications would occur shortly after admission. 
Nursing home residents were considered opioid-naïve if they had not used a short- or a 
long-acting opioid in the 60 days preceding initial receipt of a long-acting opioid after 
nursing home admission.   
Correlates 
 Correlates were selected based on previous literature and drawn from MDS 
assessments and drug dispensing records. They included the key sociodemographic and 
clinical characteristics listed in Table 1-1. 
1.3.4 Statistical Analysis 
Descriptive Statistics (Aims 1, 2, and 3) 
We presented means, standard deviations, and ranges for continuous variables and 
proportions for categorical variables. We compared means using t-tests and proportions 
using Chi-square tests. 
 
 
17 
 
Multivariable Analysis (Aims 1 and 3) 
 We developed a multinomial logistic model to estimate the effects of resident-
level characteristics on the likelihood of having pain (Aim 1), and binary logistic models 
to estimate the likelihood of receiving an analgesic (Aim 1) and naïve initiation of a long-
acting opioid after nursing home admission (Aim 3). Before constructing the models, we 
calculated correlations among variables. If variable pairs were highly collinear (>0.90), 
only one of the variables was included in the final models. The logistic models were fit 
using robust estimation of standard errors to adjust for clustering effects of residents 
within nursing homes.53 
 In Aim 1, models were manually constructed in a step-wise fashion, with 
variables with P ≤0.25 in univariate tests retained in the final models. Based on previous 
work,6 we did not anticipate interactions among covariates; however, we evaluated and 
ruled out interactions. We used the Hosmer-Lemeshow test to evaluate goodness-of-fit, 
and McFadden pseudo-R2 and the c-statistic to assess model discrimination, with a c-
statistic 0.80 indicating a strong model.54  
In Aim 3, models were adjusted for all correlates of interest. Adjusted odds ratios 
(ORs) and 95% confidence intervals (CIs) were derived from the final models. 
Time Series Analysis (Aim 2)  
 Interrupted time series, a strong quasi-experimental research design well-suited 
for evaluations of time-delimited interventions,55 was used to assess the longitudinal 
effects of Medicare Part D on fentanyl patch and other opioid use. First, time series data 
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were visually analyzed for noticeable changes in level and trend of opioid use between 
the time segments before and after Medicare Part D implementation. Second, segmented 
regression analysis was used to assess whether changes in level and trend were the result 
of chance or factors other than Medicare Part D. A least squares regression line was fit to 
each segment of the predictor, time; however, after evaluation of the linearity of the 
relationship between prescribing rates and time within each of the two time segments, we 
decided to fit a Poisson model that is more appropriate for counts of rare events.56 We 
developed a segmented regression model using a generalized linear model approach to 
estimate the immediate change in the prescribing rate level and the gradual change in 
trend after the implementation of Medicare Part D, adjusting for baseline level and trend. 
The basic model is: 
                                                       
where     is the prevalence of opioid use per month  ;      is the underlying time trend 
(a continuous variable indicating time in months at time   from the start of the 
observation period);       is an indicator for time   occurring before           or 
after Medicare Part D          , which was implemented at month 13 in the series; 
and                   is a continuous variable indicating the number of months after 
Part D at time  , coded 0 before Medicare Part D and           after Medicare Part D. 
   estimates the baseline level of opioid use prevalence per month;    estimates the 
change in opioid use prevalence that occurs each month before Medicare Part D (i.e., the 
baseline trend);    estimates the level change in opioid use prevalence immediately after 
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Medicare Part D implementation; and    estimates the change in the trend in opioid use 
prevalence after Medicare Part D implementation, compared with the monthly trend 
before Medicare Part D. The sum of    and    represents the post-Medicare Part D slope. 
The error term,    , at time   represents the random variability not explained by the 
model. Specifically,    consists of a normally distributed random error and an error term 
at time   that may be correlated to errors at preceding or subsequent time points. We 
adjusted this basic model for rates for January 2006 (a dummy variable for this transition 
month), and evaluated and ruled out seasonal effect (dummy variables for quarters in 
each calendar year).  
 Error terms of consecutive observations may be correlated, and failure to correct 
for this may lead to an underestimation of standard errors and an overestimation of the 
effects of Medicare Part D.55 Autocorrelation of the error terms in the segmented 
regression model were evaluated by visual inspection of residual plots and the Durbin-
Watson statistic.57,58 Random patterns among residuals plotted against time indicated no 
autocorrelations; positive and negative autocorrelations would have been indicated if 
consecutive residuals lined on the same side or different sides of the regression line, 
respectively.57 A Durbin-Watson test statistic of 2.00 indicated no serious 
autocorrelation.58 However, we fit our segmented regression models using Newey-West 
standard errors to account for possible serial correlation of consecutive observations.59  
 Adjusted incidence rate ratios (IRR) and 95% CIs were derived from the final 
models. P≤0.05 (two-tailed) was considered statistically significant.   
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1.4 Innovations and Impact 
 The innovation of this dissertation lies in its topic area and the unique data 
sources and methodological approaches used. First, this dissertation sought to explore a 
population not well studied – nursing home residents with cancer. Research to date has 
been limited to sub-groups of cancer patients in nursing homes, specifically those who 
were admitted to the nursing home from a hospital6 or decedents with comorbid 
dementia.33,34 This dissertation provides new evidence relevant to a broad population of 
cancer patients in nursing homes. It contributes much-needed empirical evidence on the 
pharmaceutical management of cancer-related pain in nursing homes, a critical public 
health issue of increasing importance. The most comprehensive evaluation of cancer-
related pain management in this setting5 was based on data from nearly 20 years ago and, 
in the years since, the landscape of pain management in nursing homes may have 
changed. By examining access to appropriate and effective pain management among 
cancer patients in US nursing homes, this dissertation promotes research on quality of 
health care services in a particularly vulnerable segment of the older adult population. 
Second, we used in Aims 1 and 2 a unique, nationally-representative administrative 
database spanning a variety of payment sources, including Medicare, Medicaid, private 
insurance, cash, and facility/hospice. Previous studies have examined only single-payer 
data sources such as Medicaid and Medicare. This innovative dataset permits the 
evaluation of all patients with cancer-related pain in nursing homes, regardless of payer 
status. Third, we used the richness of this longitudinal data source to understand naïve 
initiation of long-acting opioids. Such detailed information may provide new 
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opportunities for improving pain management in this setting. Additionally, the increasing 
use of nursing homes as a setting for cancer care, and the shift of most nursing home 
residents from Medicaid to Medicare Part D as the payer for medication in this setting, 
underscores the need for an evaluation of the impact of Medicare Part D on this often 
understudied, yet vulnerable, population. Fourth, the use of segmented regression of 
interrupted time series to empirically evaluate the impact of a national policy change on 
opioid use is novel. This analytic method is considered to be the strongest quasi-
experimental design to evaluate the effects of time-delimited interventions.55 
 The significance of this work rests with the potential to stimulate change in health 
policy and practice through the provision of needed information about the potential 
unintended effect of Medicare Part D on older men and women with cancer experiencing 
pain. As the first empirical evaluation of Medicare Part D’s impact on opioid use among 
patients with cancer in nursing homes, this dissertation provides stimulus for enhanced 
Medicare Part D coverage of essential pain medication for Medicare beneficiaries 
residing in nursing homes. In particular, opioids may be considered a protected drug class 
that Medicare Part D prescription drug plan formularies are expected to carry. In 
addition, this dissertation offers new information that could promote new directions for 
interventions to enhance the quality of cancer-related pain management in nursing homes 
nationwide. Study results may have direct implications for long-term care clinical 
practice and policy by providing measures of cancer-related pain and analgesic use to 
inform targets for nursing home quality improvement efforts. Shortly after publication of 
the first evaluation of cancer-related pain management quality among nursing home 
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residents,5 CMS quality indicators focusing on pain management in nursing homes were 
implemented and publicly reported.60,61 Similarly, the Robert Wood Johnson Foundation 
launched a national program, “Targeted End-of-Life Projects Initiative,” to improve care 
at the end of life. A 1999 recommendation from this initiative was that states should 
assess whether their laws and regulations inadvertently act as barriers to pain 
management by discouraging the use of opioids.62  
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Table 1-1: Variable Definitions, Coding, and Source 
Variable Definition Coding Source 
Sociodemographics    
Age  Categorical: <65, 65–74, 75–
84, ≥85 
Drug dispensing records, MDS 
3.0 
Sex  Dichotomous MDS 2.0, 3.0 
Race/ethnicity  Categorical: non-Hispanic 
white, non-Hispanic black, 
Hispanic, Asian, Native 
Hawaiian or other Pacific 
Islander, American Indian or 
Alaska Native, multiracial 
MDS 2.0, 3.0 
Marital status  Categorical: never married, 
married, widowed, separated or 
divorced 
MDS 2.0 
Region US Census Region Categorical: South, West, 
Midwest, Northeast 
Drug dispensing records 
Clinical Characteristics    
Source of admission  Categorical: acute care hospital, 
private home, other nursing 
home, other 
MDS 2.0, MDS 3.0 
Functional status Score on Activities of Daily 
Living (ADL) Hierarchy Scale41 
Categorical. Scores are between 
0 and 6, where: 
5–6 = severe impairment 
3–4 = moderate impairment 
0–2 = no/mild impairment 
MDS 2.0 
 Resource Utilization Groups-III 
ADL Score46 
Categorical. Scores are between 
4 and 18, where: 
17–18 = severe impairment 
14–16 = moderate impairment 
0–14 = no/mild impairment 
MDS 3.0 
Cognitive status Score on Cognitive Performance Categorical. Scores are between MDS 2.0 
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Variable Definition Coding Source 
Scale43 0 and 6, where: 
5–6 = severe impairment 
2–4 = moderate impairment 
0–1 = no/mild impairment 
Score on Cognitive Function 
Scale47 
Categorical: cognitively intact, 
mild impairment, moderate 
impairment, severe impairment 
MDS 3.0 
Depressed mood Score on Depression Rating 
Scale42 
Categorical. Scores are between 
0 and 14, where: 
3 = indication of major or 
minor depressive disorder 
MDS 2.0 
Terminal prognosis Life expectancy of <6 months or 
receipt of hospice care 
Dichotomous MDS 2.0, MDS 3.0 
Bedfast  Dichotomous MDS 2.0 
Parenteral feeding/feeding tube  Dichotomous MDS 2.0, MDS 3.0 
Indwelling catheter  Dichotomous MDS 2.0 
Restraints Trunk and limb restraints and 
chairs to prevent rising 
Dichotomous MDS 2.0 
Difficulty chewing  Dichotomous MDS 3.0 
Difficulty swallowing  Dichotomous MDS 3.0 
Rejected care  Dichotomous MDS 3.0 
Number of diagnoses  Continuous MDS 2.0 
Alzheimer disease  Dichotomous MDS 3.0 
Arthritis e.g., degenerative joint disease, 
osteoarthritis, rheumatoid arthritis 
Dichotomous MDS 2.0, MDS 3.0 
Asthma, chronic obstructive 
pulmonary disease, or chronic 
lung disease 
 Dichotomous MDS 3.0 
Cancer With or without metastasis Dichotomous MDS 3.0 
Heart failure e.g., congestive heart failure, 
pulmonary edema 
Dichotomous MDS 3.0 
Hip fracture e.g., sub-capital fractures, Dichotomous MDS 2.0, MDS 3.0 
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Variable Definition Coding Source 
fractures of the trochanter and 
femoral neck 
Osteoporosis  Dichotomous MDS 2.0, MDS 3.0 
Respiratory failure  Dichotomous MDS 3.0 
Stroke  Dichotomous MDS 3.0 
Number of medications  Continuous Drug dispensing records 
Outcome Variables    
Pain Any pain in the 7 days preceding 
assessment 
Dichotomous MDS 2.0 
Any pain in the 5 days preceding 
assessment 
Dichotomous MDS 3.0 
     Frequency  Categorical: no pain, less than 
daily, daily 
MDS 2.0 
 Categorical: rarely, 
occasionally, frequently, almost 
constantly 
MDS 3.0 
     Intensity  Categorical: mild, moderate 
pain, severe   
MDS 2.0 
Numeric rating scale Categorical. Scores are between 
0 and 10, with: 
0 = no pain 
1–4 = mild  
5–7 = moderate 
8–9 = severe 
10 = very severe/horrible63 
MDS 3.0 
Verbal descriptor scale Categorical: mild, moderate, 
severe, very severe/horrible 
MDS 3.0 
Receipt of analgesics   Dichotomous Drug dispensing records 
     Receipt of WHO level 1  
     drug 
Any record for: 
 Nonsteroidal anti-
inflammatory drugs 
 acetaminophen 
Dichotomous Drug dispensing records 
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Variable Definition Coding Source 
     Receipt of WHO level 2 
     drug 
Any record for: 
 codeine 
 hydrocodone 
 propoxyphene 
 pentazocine 
 nalbuphine 
 butorphanol 
 standardized opium 
 tramadol 
 combinations of these 
drugs with WHO level 1 
drug 
Dichotomous Drug dispensing records 
     Receipt of WHO level 3  
     drug 
Any record for: 
 morphine 
 hydromorphone 
 oxycodone 
 oxymorphone 
 buprenorphine 
 methadone 
 meperidine 
 levorphanol 
 fentanyl 
Dichotomous Drug dispensing records 
Receipt of adjuvants Any record for: 
 corticosteroids 
 muscle relaxants 
 gabapentin 
 pregabalin 
 tricyclic antidepressants 
 selective norepinephrine 
reuptake inhibitors 
 alpha-2-adrenergic 
Dichotomous Drug dispensing records 
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Variable Definition Coding Source 
agonists 
 transdermal lidocaine 
 mexiletine  
     Receipt of long-acting  
     opioid 
Any record for: 
 Avinza® (morphine sulfate 
extended-release) 
 Butrans® (transdermal 
buprenorphine system) 
 Duragesic® (transdermal 
fentanyl system) 
 Exalgo® (hydromorphone 
hydrochloride extended-
release) 
 Kadian® (morphine sulfate 
extended-release) 
 MS Contin® (morphine 
sulfate controlled-release) 
 Opana ER® (oxymorphone 
hydrochloride controlled-
release) 
 Oxycontin® (oxycodone 
hydrochloride controlled-
release) 
 Ultram ER® (tramadol 
hydrochloride) 
 methadone  
Dichotomous Drug dispensing records 
     Receipt of short-acting  
     opioid 
Any record for immediate-release 
formulations of: 
 buprenorphine 
 butorphanol 
 codeine 
Dichotomous Drug dispensing records 
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Variable Definition Coding Source 
 fentanyl citrate 
 hydrocodone 
 hydromorphone 
 meperidine 
 morphine sulfate 
 nalbuphine 
 opium 
 oxymorphone 
 oxycodone 
 pentazocine 
 tapentadol 
 tramadol 
 combinations of these 
drugs with WHO level 1 
drugs52   
     Receipt of oral opioid   Dichotomous Drug dispensing records 
     Receipt of transdermal  
     opioid  
 Dichotomous Drug dispensing records 
     Receipt of  intravenous or   
     Intramuscular opioid 
 Dichotomous Drug dispensing records 
     Receipt of suppository  
     opioid 
 Dichotomous Drug dispensing records 
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CHAPTER II:  
PAIN MANAGEMENT IN NURSING HOME RESIDENTS WITH CANCER 
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ABSTRACT 
BACKGROUND: In the mid-1990s, 29.4% of nursing home residents with cancer suffered from 
daily pain, and among them 26% failed to receive any analgesics. Our objective was to assess 
improvements in pain management of nursing home residents with cancer since the 
implementation of pain management quality indicators. 
METHODS: This cross-sectional study included 8,094 newly-admitted, Medicare-eligible 
nursing home residents with cancer admitted to 1,382 US nursing homes. Nationwide data from 
the MDS 2.0 linked to all-payer pharmacy dispensing records (February 2006-June 2007) were 
used to determine prevalence of pain, including frequency and intensity, and receipt of non-
opioid and opioid analgesics. Multinomial logistic models evaluated resident-level correlates of 
pain and binomial logistic models identified correlates of untreated pain. 
RESULTS: More than 65% of nursing home residents with cancer had any pain (28.3% daily, 
37.3% less than daily), among whom 13.5% had severe and 61.3% had moderate pain. Women, 
residents admitted from acute care or who were bedfast, and those with compromised ADLs, 
depressed mood, indwelling catheter, or terminal prognosis were more likely to have pain. More 
than 17% of residents in daily pain (95% CI: 16.0–19.1%) received no analgesics, including 
11.7% with daily severe pain (95% CI: 8.9–14.5%) and 16.9% with daily moderate pain (95% CI: 
15.1–18.8%). Treatment was negatively associated with age ≥85 years (adjusted OR = 0.67, 95% 
CI: 0.55–0.81 versus aged 65–74), cognitive impairment (adjusted OR=0.71, 95% CI: 0.61–0.82), 
presence of feeding tube (adjusted OR = 0.77, 95% CI: 0.60–0.99), and restraints (adjusted OR = 
0.50, 95% CI: 0.31–0.82). 
CONCLUSION: Untreated pain is still common among nursing home residents with cancer and 
persists despite pain management quality indicators.   
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2.1 Introduction  
 Nursing homes are becoming an essential provider of cancer care for those whose 
complex health needs require continuous care. Among an estimated 1.4 million nursing 
home residents,4 9% have a cancer diagnosis at admission.5 Approximately 31.3% of 
Medicare beneficiaries with cancer receive nursing home care in the three months before 
death, and 17.1% ultimately die in this setting.30 Nursing homes are expected to carry 
more of the burden of cancer care delivery, given a 40% lifetime risk of nursing home 
placement after age 65 years,26–28 rising prevalence of cancer among a growing older 
adult population, and improvements in life expectancy after a cancer diagnosis.29  
 Pain is the most common symptom in older adults with cancer,17,18 and pain 
management is critical to providing optimal care to these patients. Widely regarded as the 
“fifth vital sign,”64 pain deserves prompt evaluation and treatment. Clinical practice 
guidelines published by the WHO49 serve as the foundation for guidelines by the 
American Society of Anesthesiologists,50 European Society for Medical Oncologists,51 
and the National Comprehensive Cancer Network,10 and have been shown to be 80–90% 
effective at managing cancer-related pain overall.9,24,25 However, pain among patients 
with cancer is known to be undertreated in nursing homes. The most comprehensive 
evaluation thus far of pain management among nursing home residents with cancer, 
published in 1998, found that 29.4% of residents with cancer suffered from pain on a 
daily basis.6 More than a quarter of those with daily pain failed to receive analgesics, and 
lack of treatment was significantly associated with advanced age, minority race, and 
cognitive impairment.6 Similarly, studies of nursing home residents with comorbid 
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dementia and advanced cancer showed inverse relationships between cognitive ability 
and pain-related behaviors, and between cognitive ability and dose of opioid 
medication.33,34 
 National efforts have since been made to improve upon the quality of nursing 
home care, including the public reporting of the CMS pain management quality 
indicators beginning in 2002.60 An update to our current understanding of pain 
management among nursing home residents with cancer is needed. Therefore, we 
examined the use of analgesics among more than 8,000 cancer patients residing in US 
nursing homes in 2006 and 2007. Specifically, we estimated the prevalence and resident-
level correlates of pain and receipt of analgesics among newly-admitted older and 
disabled nursing home residents with cancer.  
2.2 Methods 
 The institutional review board of the University of Massachusetts Medical School 
approved this study. 
2.2.1 Data Sources 
 We used the most recent data available from a nationwide long-term care 
pharmacy, including nursing home resident health assessments from the MDS version 2.0 
linked with an all-payer administrative data source of all dispensed prescription and over-
the-counter medication.  
 The MDS is a federally-mandated comprehensive clinical assessment of all 
residents in Medicare- or Medicaid-certified nursing facilities (approximately 96% of US 
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facilities). It consists of more than 400 items, including sociodemographic information, 
clinical items (e.g., communication, mood and behavior, signs, symptoms), clinical 
diagnoses, and treatments provided.40,65 It includes multi-item summary scales for 
measures of functional status (ADL Hierarchy Scale),41,66 cognitive status (Cognitive 
Performance Scale),43 and depressed mood (Depression Rating Scale).42 Nursing staff are 
required to perform full assessments at admission and annually, as well as reduced 
assessments on a quarterly basis or after a significant change in resident health.65 A 
registered nurse performs the assessment of a resident’s status over the previous week 
based on medical record review, direct observation of and communication with the 
resident, family interviews, and discussions with the resident’s medical and direct care 
teams.  
2.2.2 Study Sample 
 As shown in Figure 2-1, the sampling frame for this study was 166,139 nursing 
home residents with MDS assessments performed between February 1, 2006, and June 
30, 2007. We excluded nursing home residents without a diagnosis of cancer indicated on 
MDS assessment (n = 142,654); those admitted to the nursing home before February 
2006 (n = 13,452); residents whose prescriptions could not be identified using NDCs (n = 
1,633); those who were Medicare-ineligible, defined as aged <65 years without ≥1 
Medicare-paid prescription drug (n = 25); comatose residents (n = 7); and those missing 
information on important sociodemographic and clinical characteristics (n = 274). The 
final sample size was 8,094 residents admitted to 1,382 nursing homes.  
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2.2.3 Measurement of Pain 
Section J of the MDS 2.0 allowed for evaluation of pain, defined as any type of 
physical pain or discomfort in any part of the body, occurring in the seven days preceding 
the assessment. The valid67 and reliable48 pain-related items address two general 
characteristics of pain: frequency (no pain, pain less than daily, pain daily) and intensity 
(mild pain, moderate pain, times when pain is horrible or excruciating (severe)). Nursing 
staff used a checklist to specify site of pain (e.g., bone, soft tissue). A “skip pattern” 
allowed the assessor to skip the items on intensity and site of pain if there was no pain 
present. Instructions for these measures recommended reliance on resident report 
whenever possible, although staff and family observations, physician records, or medical 
charts could also have been used.65 For residents who were unable to communicate, 
nursing staff were instructed to look for non-verbal cues of pain, such as grimacing or 
moaning. 
2.2.4 Measurement of Analgesic Use 
 To evaluate the quality of medication use at the beginning of nursing home 
admission, we identified all drugs dispensed within seven days of a resident’s first 
prescription date. Drug dispensing records were available from February 1, 2006, to June 
30, 2007. Data elements included all drugs prescribed and administered to nursing home 
residents, prescription date, product code (NDC), days’ supply, quantity dispensed, and 
payment source. A database provided by the long-term care pharmacy was used to 
translate NDCs into therapeutic classes and subclasses. 
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Opioids are central to existing clinical practice guidelines for management of 
cancer-related pain. To allow for comparisons with previous work,6 analgesics were 
classified into three groups according to the WHO’s three-level “ladder” for cancer pain 
relief.49 Non-opioids (level 1) included non-steroidal anti-inflammatory drugs and 
acetaminophen. Aspirin was not considered an analgesic medication because it is 
typically used among older adults as anti-platelet therapy.68 Opioids commonly used for 
mild to moderate pain (level 2) included codeine, hydrocodone, propoxyphene, 
meperidine, pentazocine, nalbuphine, butorphanol, and any combination of these drugs 
with level 1 drugs. Opioids commonly used for moderate to severe pain (level 3) included 
morphine, hydromorphone, oxycodone, buprenorphine, oxymorphone, methadone, 
levorphanol, and fentanyl. Per more recent clinical practice guidelines that consider pain 
management by level of opioid-tolerance and alternative modes of administration,10,50,51 
we categorized opioid analgesics by duration of effect (short-acting, long-acting) and by 
formulation (oral, intravenous/intramuscular, transdermal, suppository). We considered 
adjuvant medications used for pain management alone or in combination with analgesics. 
Since indication was absent from drug dispensing records, we identified medication 
broadly applicable to pain management, including corticosteroids, muscle relaxants, 
anticonvulsants (i.e., gabapentin, pregabalin), tricyclic antidepressants, selective 
norepinephrine reuptake inhibitors, alpha-2-adrenergic agonists, transdermal lidocaine, 
and mexiletine.68   
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2.2.5 Statistical Analysis 
We evaluated age trends of resident-level characteristics using likelihood chi-
square tests for categorical variables and non-parametric tests (e.g., Kruskal-Wallis test) 
for continuous variables with skewed distributions. We used multinomial logistic 
regression models to estimate association among resident characteristics and pain, 
measured on three levels: daily, less than daily, and none. Binary logistic regression was 
used to evaluate association among resident characteristics and receipt of analgesics 
among residents with any pain. To facilitate comparison with published estimates of daily 
pain and receipt of analgesic medication among nursing home residents with cancer,6 we 
performed sensitivity analyses on a reduced study sample of nursing home residents ≥65 
years who were admitted to the nursing home from an acute care hospital (n = 6,610). We 
also separately evaluated receipt of opioid analgesics among nursing home residents with 
moderate-to-severe pain (n = 3,973).  
 Regression models were fit using robust estimation of standard errors to account 
for correlation between residents within the same nursing home.69 Models were manually 
constructed in a step-wise fashion. We first evaluated crude associations between each 
variable and the outcome and, at each stage of model building, selected the strongest 
variable for inclusion and considered the remaining variables in the presence of those 
selected for the model. We evaluated correlations among covariates, and if variable pairs 
were highly collinear (>0.90), only one of the variables was included in the final models. 
Risk estimates are presented as unadjusted and adjusted ORs and 95% CIs. P0.05 (2-
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tailed) was considered statistically significant. All analyses were performed using Stata 
version 11.2 (StataCorp LP, College Station, TX).  
2.3 Results 
 Newly-admitted nursing home residents had a mean age of 80.0 ± 9.1 years 
(range: 29.0–105.6 years) and were predominately female (53.1%), non-Hispanic white 
(83.2%), and admitted from an acute care hospital (86.2%). Nearly 74% and 45% of 
residents had moderate-to-severe impairment in ADLs and cognition, respectively, with 
prevalence of both increasing with age (P<0.001 for age trend; Table 2-1). Similarly, the 
mean number of medical conditions increased with age (P<0.001). Conversely, the 
prevalence of depressed mood and mean number of medications decreased with age (both 
P<0.001).  
2.3.1 Pain 
 More than 65% of residents with cancer had documented pain, 28.3% had daily 
pain (95% CI, 27.3–29.2%) and 37.3% had less frequent pain (95% CI, 36.3–38.4%) 
documented. Daily pain decreased with age (P<0.001 for age trend; Table 2-1), while 
less frequent pain increased with age (P<0.001). Clinical conditions potentially 
associated with pain, including arthritis, osteoporosis, and hip fractures, were more 
prevalent with increasing age (P<0.001).  
 Compared to residents aged 65–74 years, older residents were less likely to have 
pain documented on a daily basis or less (Table 2-2). Independent of age, those with 
cognitive impairment, feeding tubes, or who were restrained were less likely to have 
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daily pain recorded. Conversely, women, residents admitted from a hospital, those with 
compromised ADLs, depressed mood, an indwelling catheter or an explicit terminal 
prognosis, or who were bedfast had increased odds of pain. Results were consistent in 
sensitivity analysis of nursing home residents ≥65 years admitted from a hospital (Table 
A-1); however, non-Hispanic blacks were less likely than non-Hispanic whites to have 
documented pain.     
2.3.2 Receipt of Analgesics 
 Analgesics comprised 9.5% of medications dispensed within the first week of 
nursing home admission. More than half of nursing home residents (58.8%) received an 
analgesic (mean 1.8 ± 0.9, range: 1–8). Nearly 12% received at least one non-opioid, 
46.6% at least one level 2 drug, and 15.3% at least one level 3 drug. Specifically, 51.5% 
received a level 2 drug only, 7.7% received a non-opioid only, and 9.6% received a level 
3 drug only. One-fifth received multiple analgesics of varying strength according to the 
WHO three-level ladder (7.1% received a non-opioid plus a level 2 drug; 1.4%, a non-
opioid plus a level 3 drug; 10.9%, a level 2 drug plus a level 3 drug; and 1.4%, all three). 
Hydrocodone was the most commonly prescribed analgesic (comprising 26.7% of 
analgesic prescriptions), followed by oxycodone (19.1%), fentanyl (9.1%), and 
propoxyphene (8.9%, withdrawn from the US market in 201033). Approximately 36% of 
residents with daily severe pain and 21% of residents with daily moderate pain used long-
acting opioids (Table 2-3).    
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Overall, 27.6% of nursing home residents with documented pain received no 
analgesics (95% CI: 26.4–28.9%). Among those in daily pain, 17.5% received no 
analgesics (95% CI: 16.0–19.1%), including 11.7% whose daily pain was severe (95% 
CI: 8.9–14.5%) and 16.9% whose daily pain was moderate (95% CI: 15.1–18.8%). More 
than 35% of residents with less frequent pain did not receive treatment (95% CI: 33.6–
37.0%), including 21.5% with severe pain (95% CI: 15.8–27.1%) and 28.3% with 
moderate pain (95% CI: 26.2–30.4%). There were no differences by pain severity with 
respect to problems swallowing (P=0.185), but those with moderate pain were more 
likely than those with mild or with severe pain to have medication restrictions 
documented in their medical record (P <0.001). Those with untreated pain were less 
likely than those with treated pain to receive an adjuvant medication (17.2% vs. 25.0%, 
P<0.001). 
 Relative to residents aged 65–74 years, older residents were less likely to receive 
analgesics for their pain, although the 95% CI included unity for those aged 75–84 years 
(Table 2-4). Similarly, those with cognitive impairment, feeding tubes, and restraints 
were less likely to receive analgesics. Conversely, women were more likely than men to 
receive treatment. Receipt of analgesics was also positively associated with nursing home 
admission from a hospital, increasing number of non-analgesic medications, and terminal 
prognosis. Results were generally consistent in sensitivity analyses of older nursing home 
residents admitted from a hospital (Table A-2) and of nursing home residents in 
moderate-to-severe pain (Table A-3). However, the latter sensitivity analysis did not find 
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a statistically significant association of opioid treatment among women and residents who 
used restraints.  
2.4 Discussion  
 This study reveals that the majority (65.6%) of nursing home residents with a 
cancer diagnosis experience pain. A substantial proportion of that pain is daily, and 
moderate to severe in intensity. Between 2006 and 2007, 17.6% of nursing home 
residents with daily pain lacked treatment with analgesics in the first week of nursing 
home admission. These results are only modestly decreased from those documented 
before national efforts to improve the quality of pain management in nursing homes.  
 Between 1992 and 1995, approximately 26% of nursing home residents in daily 
pain did not receive any analgesic agent.6 Earlier estimates of medication receipt may be 
underreported due to a reliance on pharmacist- and nurse-reported medication lists 
(Section U of the MDS). Our use of long-term care pharmacy dispensing records offers 
improved identification of analgesic treatment. Because Section U was removed from the 
MDS, we were unable to disentangle the extent to which the observed improvement in 
pain management may be an artifact of differences in measurement methodology rather 
than a true shift in practice patterns.  
 We anticipated improvements in pain management since the mid-1990s for 
several reasons. The CMS nursing home quality indicators focused on pain were tested 
beginning in 1998,70 and public reporting of the prevalence of uncontrolled pain began in 
2002.60 Thirteen states have passed or updated legislation since 1998 to improve access to 
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scheduled drugs for treatment of intractable pain.71 In addition, the Federation of State 
Medical Boards published their Policy on the Use of Opioid Analgesics in the Treatment 
of Chronic Pain encouraging the adequate treatment of patients in pain and appropriate 
use of opioids,72 and nearly 30 states have adopted the Policy for their own policies. 
Despite these efforts, untreated pain remains a significant problem among nursing home 
residents with cancer.   
 Further, among this medically-needy patient population, a number of particularly 
vulnerable sub-groups continue to be at higher risk of having their pain go untreated. 
Consistent with previous findings,6,33,34 we found that the oldest old and those with 
cognitive impairment were more likely to not receive treatment for their documented 
pain. Despite the widespread dissemination of clinical guidelines for pain management in 
older adults, adequate pain management among older adults may be complicated by the 
presence of comorbid conditions, increased risk of adverse effects, and physician factors 
such as inadequate training or reluctance to prescribe opioids.73 Cognitive impairment 
may preclude nursing home residents from effectively communicating their need for pain 
relief. Although nursing staff have detailed instructions on pain assessment in non-verbal 
residents,65 providers may continue to rely on patients’ verbal reports when deciding to 
treat pain.74 Indeed, even in our sensitivity analysis of nursing home residents with 
documented moderate-to-severe pain, those with cognitive impairment were less likely to 
receive analgesic medication. 
 Facility-level characteristics have been shown to impact quality of pain 
management among nursing home residents. For example, residents whose cancer was 
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diagnosed after nursing home admission were less likely to receive pain medication in 
facilities with a high Medicaid patient load or with a higher Medicare-paid percentage of 
days.75 While it was beyond the scope of this study to evaluate organizational factors 
related to receipt of analgesics, we found that nursing home residents with feeding tubes 
or restraints—devices known to be associated with poor nursing home quality76,77—had 
decreased odds of receiving analgesics for their documented pain. This study provides 
additional evidence that nursing home quality is associated with quality of care provided 
to residents.     
 The present study has several strengths worth highlighting. First, it is a much-
needed update to what is already known about pain management among nursing home 
residents with cancer. While our evaluation of daily pain permits comparisons with 
previous research, we also provide new evidence around more nuanced facets of pain, 
including pain intensity and the prevalence and treatment of infrequent pain. Second, we 
provide new evidence on pain management that is relevant to a broader population of 
nursing home residents with cancer. Indeed, study participants were drawn from a 
national sample of nursing homes across 46 states and were admitted to the nursing home 
from both acute and non-acute settings. Third, data were from newly-admitted nursing 
home residents and thus permitted evaluation of medication quality at the beginning of a 
nursing home stay. Fourth, we used a unique prescription dispensing data source that 
spanned all payers (i.e., Medicare Parts A/B, Medicare Part D, Medicaid, third party 
private insurance, cash, and facility/hospice) and thus represented all types of nursing 
home residents. Previous studies of analgesic medication use in nursing homes have 
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examined only beneficiaries of single-payer sources.31,32 Finally, our data source included 
over-the-counter as well as prescription medications dispensed to nursing home residents 
during the study period, allowing for prevalence estimates of non-opioid analgesics.       
 There were also some limitations. We reference the WHO analgesic ladder, which 
has been subject to numerous debate and criticism78–81 owing to its omission of 
alternative routes of drug administration, nonpharmaceutical treatments, and 
interventional procedures. Despite these limitations, the WHO analgesic ladder has 
demonstrated effectiveness and widespread utility, and remains the reference point for 
cancer-related pain management.50,51 This was a cross-sectional study of pain 
management in the first week of nursing home admission, a period of great transition 
during which care processes may suffer. While we cannot comment on the quality of pain 
management among residents with longer nursing home stays, previous research has 
shown that more than half of cancer patients with pain have severe pain on subsequent 
quarterly MDS assessment.5 Although MDS 2.0 pain assessments could be augmented by 
nursing staff and family observations, concerns remain about potential misclassification 
of pain, especially among residents with difficulty communicating. Although we 
considered a resident’s pain to be treated if they had at least one dispensing record for an 
analgesic, we were unable to determine whether the treatment provided adequate pain 
relief. Therefore, our results may underestimate the true prevalence of pain and its 
treatment. We also acknowledge that it is possible that pain medications started before 
admission to the nursing home were not re-evaluated. We were not able to definitively 
attribute cancer as the underlying pathology of pain, nor were we able to specify cancer 
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type. However, guidelines on the use of analgesic medication for persistent pain among 
older adults are not cancer-specific. Although we provide prevalence estimates of 
adjuvant medication use, we were unable to evaluate non-pharmacological approaches to 
pain management owing to the absence of this information in the MDS 2.0. Future 
studies using the MDS 3.0 may be better able to evaluate these alternative approaches to 
pain management. Finally, dispensing records lacked the indication for medication use 
and information on medications used prior to nursing home admission, so we could not 
determine appropriateness of treatment. 
2.5 Conclusion 
 This study contributes a much-needed update on the quality of pain management 
among nursing home residents with cancer, a critical public health issue of increasing 
prominence. Pain remains common and undertreated among some of the most vulnerable 
cancer patients in the US, and special attention should be paid to the oldest old, those 
with cognitive impairment, and residents of potentially poor quality nursing homes. 
Among nursing home residents overall, recent national goals for prevalence of moderate-
to-severe pain were 15% for short-stay, post-acute residents and 4% for long-stay 
residents.82 Although cancer-specific targets for pain management do not currently exist, 
these data suggest that the current state of pain management among nursing home 
residents with cancer falls short of these goals. New information provided here may 
provide initial directions for targeted efforts to improve the quality of pain treatment in 
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nursing homes, including redoubled efforts to disseminate older adult-specific clinical 
practice guidelines in this setting. 
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Table 2-1: Characteristics of Newly Admitted Nursing Home Residents with Cancer, by Age Group 
 <65 years  
n = 421 
65–74 years 
n = 1,682 
75–84 years 
n = 3,459 
≥85 years 
n = 2,532 
Women 56.3 52.7 51.1 55.6 
Race and ethnicity     
     Non-Hispanic white 73.4 76.5 83.7 88.7 
     Non-Hispanic black 18.8 15.6 10.2 6.8 
     Hispanic 4.0 5.6 4.0 3.0 
     Asian or Pacific  
     Islander 
3.1 2.1 2.0 1.3 
     American Indian or  
     Alaskan Native 
0.7 0.2 0.1 0.2 
Source of admission     
     Acute care hospital 86.9 89.8 87.2 82.4 
     Private home 4.8 4.4 6.2 8.2 
     Other nursing home 4.5 3.0 3.8 5.2 
     Othera 3.8 2.8 2.9 4.3 
Widowed 12.1 28.5 42.1 62.4 
Degree of functional  
     impairmentb 
    
     Moderate 39.9 44.5 49.3 49.0 
     Severe 27.1 27.2 26.0 26.7 
Degree of cognitive  
     impairmentc 
    
     Moderate 24.0 29.3 40.5 50.8 
     Severe 4.3 3.2 4.3 4.9 
Depressed moodd 13.8 9.0 7.8 7.6 
Bedfast 5.5 5.8 4.6 3.7 
Terminal prognosise 8.3 8.9 8.4 7.3 
Number of diagnoses 5.5 ± 2.6 (1–15) 5.7 ± 2.5 (1–19) 6.1 ± 2.5 (1–16) 6.2 ± 2.4 (1–16) 
Clinical conditions     
     Arthritis 12.6 18.4 22.8 27.6 
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 <65 years  
n = 421 
65–74 years 
n = 1,682 
75–84 years 
n = 3,459 
≥85 years 
n = 2,532 
     Osteoporosis 4.8 8.2 11.7 15.3 
     Hip fracture 3.3 5.3 6.6 9.3 
Number of medications  
     in first week 11.1 ± 5.7 (1–35) 9.9 ± 5.4 (1–35) 9.2 ± 4.9 (1–33) 7.9 ± 4.5 (1–31) 
     Number of non- 
     analgesics in first  
     week 9.9 ± 5.4 (0–34) 8.9 ± 5.1 (0–34) 8.3 ± 4.7 (0–32) 7.2 ± 4.2 (0–28) 
Pain frequencyf     
     Daily 43.2 35.1 28.0 21.7 
     Less than daily 33.5 37.0 37.6 37.8 
 
N = 8,094 
Percentage or mean ± standard deviation (range) shown 
a Includes board and care/assisted living/group home, psychiatric hospital, rehabilitation hospital. 
b Based on 7-level scale: Activities of Daily Living Hierarchy Scale score of 3 or 4 for moderate impairment, 5 or 6 for severe 
impairment.41  
c Based on 7-level scale: Cognitive Performance Scale score of 2 to 4 for moderate impairment, 5 or 6 for severe impairment.43 
d Based on a scale from 0–14: Depression Rating Scale scores of 3 or more indicate major or minor depressive disorders.42 
e Indicated by prognosis of <6 months or receipt of hospice. 
f As assessed by nursing home staff over a 7-day period. 
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Table 2-2: Correlates of Pain in Newly Admitted Nursing Home Residents with Cancer 
 
Pain frequency 
Daily pain vs. 
no pain (referent) 
< Daily pain vs. 
no pain (referent) 
 
Daily 
n = 2,291 
 
 
< Daily 
n = 3,022 
 
 
None 
n = 2,781 
 
Unadjusted  
OR  
(95% CI) 
Adjusteda  
OR  
(95% CI) 
Unadjusted  
OR   
(95% CI) 
Adjusteda  
OR  
(95% CI) 
Age, years        
     <65 7.9 4.7 3.5 1.48 (1.11–1.96) 1.45 (1.08–1.95) 1.08 (0.82–1.42) 1.11 (0.85–1.46) 
     65–74 25.8 20.6 16.9 Referent Referent Referent Referent 
     75–84 42.3 43.1 42.7 0.65 (0.56–0.75) 0.70 (0.60–0.82) 0.83 (0.72–0.94) 0.86 (0.74–0.99) 
     ≥85 24.0 31.6 36.9 0.42 (0.36–0.50) 0.48(0.41–0.58) 0.70 (0.60–0.81) 0.75 (0.63–0.88) 
Women 59.8 54.5 46.1 1.74 (1.54–1.95) 1.67 (1.46–1.91) 1.40 (1.26–1.55) 1.35 (1.20–1.51) 
Race and ethnicity         
     Non-Hispanic  
     white 
83.9 83.9 82.0 Referent Referent Referent Referent 
     Non-Hispanic  
     Black 
10.6 9.8 11.8 0.87 (0.73–1.05) 0.87 (0.73–1.05) 0.81 (0.66–0.98) 0.82 (0.67–1.01) 
     Hispanic 3.9 4.3 3.9 0.98 (0.73–1.32) 1.01 (0.75–1.37) 1.08 (0.82–1.40) 1.06 (0.81–1.39) 
     Asian or  
     Pacific Islander 
1.4 1.9 2.1 0.66 (0.46–0.95) 0.70 (0.49–1.01) 0.87 (0.56–1.35) 0.85 (0.57–1.26) 
     American  
     Indian or  
     Alaskan Native 
0.2 0.2 0.1 1.48 (0.40–5.55) 1.60 (0.49–5.21) 1.58 (0.46–5.41) 1.49 (0.41–5.41) 
Admitted from  
     acute hospital 
88.2 87.9 82.7 1.56(1.32–1.84) 1.52 (1.27–1.82) 1.52 (1.30–1.77) 1.44 (1.23–1.69) 
Widowed 42.7 45.7 43.6 0.96 (0.86–1.08) 1.02 (0.89–1.17) 1.09 (0.98–1.21) 1.08 (0.96–1.22) 
Functional  
     impairmentb 
76.0 74.6 72.6 1.19 (1.04–1.37) 1.33 (1.15–1.54) 1.11 (0.98–1.26) 1.16(1.01–1.32) 
Cognitive  
     impairmentc 
35.9 44.0 53.0 0.50 (0.44–0.56) 0.62 (0.54–0.72) 0.70 (0.62–0.78) 0.78 (0.69–0.89) 
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Pain frequency 
Daily pain vs. 
no pain (referent) 
< Daily pain vs. 
no pain (referent) 
 
Daily 
n = 2,291 
 
 
< Daily 
n = 3,022 
 
 
None 
n = 2,781 
 
Unadjusted  
OR  
(95% CI) 
Adjusteda  
OR  
(95% CI) 
Unadjusted  
OR   
(95% CI) 
Adjusteda  
OR  
(95% CI) 
Depressed moodd 12.1 7.7 5.7 2.28 (1.82–2.84) 2.27 (1.79–2.88) 1.37 (1.11–1.70) 1.46 (1.16–1.83) 
Feeding tubes 5.0 7.9 7.5 0.65 (0.52–0.82) 0.64 (0.50–0.82) 1.06 (0.87–1.29) 1.10 (0.90–1.37) 
Indwelling  
     catheter 
27.1 24.1 19.1 1.58 (1.39–1.80) 1.52 (1.32–1.75) 1.35 (1.19–1.53) 1.28 (1.12–1.46) 
Use of restraintse 0.9 1.8 2.7 0.34 (0.20–0.56) 0.50 (0.30–0.86) 0.67 (0.47–0.94) 0.81 (0.57–1.16) 
Bedfast 6.7 4.4 3.1 2.23 (1.70–2.93) 2.06 (1.54–2.74) 1.41 (1.07–1.86) 1.37 (1.02–1.83) 
Terminal  
     prognosisf 
11.3 7.9 5.8 2.06 (1.65–2.57) 2.21 (1.73–2.83) 1.39 (1.12–1.72) 1.58 (1.26–1.98) 
 
N = 8,094 
CI: confidence interval; OR: odds ratio 
a Adjusted for all variables listed in Table 2-1 and variables describing participation in Minimum Data Set assessment (resident, family, 
significant other) and communication skills.    
b Activities of Daily Living Hierarchy Scale scores equal 3 or more.41  
c Cognitive Performance Scale scores equal 2 or more.43  
d Depression Rating Scale scores equal 3 or more.42 
e Includes trunk and limb restraints as well as chairs to prevent rising. 
f Indicated by prognosis of <6 months or receipt of hospice. 
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Table 2-3: Use of Any Analgesic Medication in First Week of Nursing Home 
Admission in Residents with Cancer and Any Pain, by Pain Intensity and 
Frequencya  
 
Pain intensity Pain frequency 
 
Daily < Daily 
Severe pain n = 512 n = 205 
     No analgesic 11.7 21.5 
     Any analgesic 88.3 78.5 
          Level 1 drug onlyb 1.0 4.9 
          Level 2 drug onlyc 37.3 40.5 
          Level 3 drug onlyd 16.8 12.7 
          Level 1 + Level 2 4.5 5.9 
          Level 1 + Level 3  2.7 1.0 
          Level 2 + Level 3 23.4 11.2 
          All   2.5 2.4 
     Adjuvante 25.6 25.4 
     Duration of effect  
     (opioids only) 
  
          Short-acting 80.9 71.2 
          Long-acting  35.7 17.1 
     Formulation  
     (opioids only) 
  
          Oral 83.8 71.7 
          Non-oralf 25.8 13.7 
               Transdermal 23.2 12.2 
               Intravenous or  
               intramuscular 
4.9 2.0 
   
Moderate pain n = 1,536 n = 1,720 
     No analgesic 16.9 28.3 
     Any analgesic 83.1 71.7 
          Level 1 drug onlyb 2.9 3.4 
          Level 2 drug onlyc 48.7 45.7 
          Level 3 drug onlyd 9.2 6.5 
          Level 1 + Level 2 6.6 6.2 
          Level 1 + Level 3  1.1 1.2 
          Level 2 + Level 3 13.2 7.6 
          All   1.4 1.1 
     Adjuvante 25.7 21.4 
     Duration of effect  
     (opioids only) 
  
          Short-acting  75.1 64.8 
          Long-acting  21.1 12.4 
     Formulation  
     (opioids only) 
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Pain intensity Pain frequency 
 
Daily < Daily 
          Oral 78.3 66.0 
          Non-oralf 14.8 9.7 
               Transdermal 13.5 8.3 
               Intravenous or  
               intramuscular 
1.7 1.4 
   
Mild pain n = 243 n = 1095 
     No analgesic 33.7 48.9 
     Any analgesic 66.3 51.1 
          Level 1 drug onlyb 4.9 9.3 
          Level 2 drug onlyc 39.1 28.5 
          Level 3 drug onlyd 3.7 4.2 
          Level 1 + Level 2 8.2 4.7 
          Level 1 + Level 3  1.6 0.5 
          Level 2 + Level 3 6.6 3.4 
          All   2.1 0.5 
     Adjuvante 23.5 19.3 
     Duration of effect  
     (opioids only) 
  
          Short-acting  59.3 39.5 
          Long-acting  9.9 5.4 
     Formulation  
     (opioids only) 
  
          Oral 60.9 39.5 
          Non-oralf 7.0 4.8 
               Transdermal 5.8 4.0 
               Intravenous or  
               intramuscular 
1.2 1.0 
 
N = 5,311 
Percentages presented may not add to 100% due to rounding. 
a Of 5,313 nursing home residents with any pain, 2 have missing pain intensity data. 
b Classified by the World Health Organization as a level 1 drug, including non-steroidal anti-
inflammatory drugs and acetaminophen. 
c Includes codeine, hydrocodone, propoxyphene, meperidine, pentazocine, nalbuphine, 
butorphanol, and any combination of these drugs with level 1 drugs. 
d Includes morphine, oxycodone, buprenorphine, hydromorphone, oxymorphone, methadone, 
levorphanol, and fentanyl. 
e Includes corticosteroids, muscle relaxants, anticonvulsants, tricyclic antidepressants, selective 
norepinephrine reuptake inhibitors, alpha-2-adrenergic agonists, transdermal lidocaine and 
mexiletine.26 
f Suppository opioid formulations were used by <0.1% of the study population. 
  
56 
 
 
Table 2-4: Correlates of Receiving Any Analgesic in Newly Admitted Nursing Home 
Residents with Cancer and Any Pain 
 
Any analgesic 
n = 3,844 
No analgesic 
n = 1,469 
Likelihood of receiving any 
analgesic for any pain 
Unadjusted 
OR  
(95% CI) 
Adjusteda 
OR  
(95% CI) 
Age     
     <65  7.0 3.8 1.41 (1.02–1.95) 1.33 (0.96–1.85) 
     65–74 24.4 18.9 Referent Referent 
     75–84 43.2 41.6 0.80 (0.68–0.95) 0.88 (0.74–1.04) 
     >85  25.5 35.7 0.55 (0.47–0.66) 0.67 (0.55–0.81) 
Women 57.6 54.6 1.13 (1.00–1.28) 1.16 (1.02–1.33) 
Race and ethnicity      
     Non-Hispanic  
     white 
84.4 82.5 Referent Referent 
     Non-Hispanic  
     black 
9.8 11.0 0.87 (0.72–1.06) 0.85 (0.69–1.05) 
     Other 5.8 6.5 0.87 (0.68–1.11) 0.81 (0.62–1.05) 
Admitted from acute  
     care hospital 88.8 86.1 1.29 (1.08–1.54) 1.25 (1.03–1.51) 
# other medication  
     in first week 
    
     <5 25.0 45.2 Referent Referent 
     6–10 40.2 32.7 2.22 (1.91–2.59) 2.46 (2.12–2.86) 
     >11 34.8 22.1 2.86 (2.41–3.39) 3.13 (2.64–3.72) 
Functional   
     impairmentc 
75.1 75.5 0.98 (0.85–1.13) 1.13 (0.97–1.32) 
Cognitive  
     impairmentd 
37.1 49.4 0.60 (0.53–0.68) 0.71 (0.61–0.82) 
Depressed moode 10.1 8.4 1.23 (0.99–1.52) 1.26 (1.00–1.58) 
Feeding tubes 6.4 7.4 0.85 (0.68–1.06) 0.77 (0.60–0.99) 
Use of restraintsf 1.0 2.4 0.43 (0.28–0.67) 0.50 (0.31–0.82) 
Bedfast 5.6 4.8 1.19 (0.89–1.59) 1.19 (0.88–1.61) 
Terminal prognosisg 9.8 8.4 1.18 (0.95–1.48) 1.45 (1.14–1.80) 
 
N = 5,313; percentages presented. 
CI: confidence interval; OR: odds ratio 
a Adjusted for all variables listed in Table 2-1 and variables describing participation in MDS 
assessment (family, significant other) and communication skills. 
b Includes Hispanic, Asian or Pacific Islander, American Indian or Alaskan Native. 
c Activities of Daily Living Hierarchy Scale scores equal 3 or more.41  
d Cognitive Performance Scale scores equal 2 or more.43  
e Depression Rating Scale scores equal 3 or more.42 
f Includes trunk and limb restraints as well as chairs to prevent rising. 
g Indicated by prognosis of <6 months or receipt of hospice. 
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CHAPTER III:  
SHOULD OPIOID PAIN MEDICATIONS RECEIVE SPECIAL MEDICARE 
PART D COVERAGE PROTECTION FOR NURSING HOME RESIDENTS 
WITH CANCER?  
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ABSTRACT 
Background: Fentanyl patches are commonly employed to treat nursing home residents with 
intractable cancer pain. However, access to fentanyl patches—among the strongest and most 
expensive of opioid formulations—may have been affected by coverage restrictions of Medicare 
Part D, the leading source of prescription drug coverage in nursing homes. Our objective was to 
evaluate Medicare Part D’s impact on use of fentanyl patches and use of less costly or less 
effective opioid analgesics among nursing home residents with cancer.   
Methods: This quasi-experimental study included 18,599 Medicare-eligible residents with cancer 
admitted to 1,112 nursing homes. We used data from the MDS 2.0 linked to all-payer long-term 
care pharmacy dispensing records (January 2005-June 2007) to estimate changes in receipt of 
fentanyl patches, other strong opioids, and weak opioids after Medicare Part D implementation. 
For each drug category, we calculated monthly proportions of residents receiving >1 prescription 
and therapy days covered. Segmented Poisson regression estimated immediate and trend changes 
in medication use after Medicare Part D, adjusting for baseline trends. 
Results: We observed increasing trends for all opioid drug categories prior to Medicare Part D. 
After Medicare Part D, receipt of fentanyl patches and other strong opioids abruptly decreased by 
10% and 21%, respectively. Residents with cancer were less likely to receive fentanyl patches 
after Medicare Part D relative to historical trends (IRR = 0.98; P<0.001), but more likely to 
receive other strong opioids (IRR, 1.01; P = 0.02). Trends in weak opioids remained unchanged.   
Conclusions:  We observed immediate and sustained reductions in the receipt of fentanyl patches 
and other opioids among nursing home residents with cancer after implementation of Medicare 
Part D. Although the clinical impact of these patterns is uncertain, this finding suggests cost-
related barriers to therapeutic options in the treatment of cancer pain in nursing homes.     
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3.1 Introduction  
Since 2006, Medicare Part D has been the leading source of prescription drug 
coverage for older adults. Under this benefit, medications fall into protected or excluded 
drug classes, or neither. Participating private prescription drug plans must include in their 
formularies “all or substantially all” drugs and unique dosage forms within six protected 
classes of medical concern: antineoplastics, antidepressants, antipsychotics, 
anticonvulsants, antiretrovirals, and immunosuppressants.11 In addition, for beneficiaries 
taking a specific medication within a protected drug class, plans are prohibited from 
employing utilization management requirements (e.g., prior authorization, step therapy) 
that would otherwise steer beneficiaries to preferred alternatives. Conversely, plans 
cannot cover medications excluded under basic Medicare Part D coverage (e.g., 
benzodiazepines, nonprescription drugs, vitamins and minerals). Formularies must 
include at least two chemically distinct drugs within the classes that are neither protected 
nor excluded.11 Given the absence of other Medicare Part D guidance on these drug 
classes, individual plans have flexibility in selecting the particular drugs covered and 
employing utilization management requirements.   
There is evidence that Medicare Part D’s exclusion of benzodiazepines led to 
disruptions in medication use and some substitutions with other psychotropic drugs.38,83–
85 Similar patterns of disruption have been observed in the nursing home setting among 
angiotensin receptor blockers, cholinesterase inhibitors, and long-acting opioids, which 
are medications that are neither protected nor excluded.86 However, the impact of 
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Medicare Part D on these and other classes of unprotected medications is not well 
understood. 
Data regarding impact of Medicare Part D on opioid use, in particular, are scant. 
Fentanyl, a potent, synthetic opioid analgesic, is indicated for persistent, moderate to 
severe pain in opioid-tolerant patients.7 Despite FDA public health advisories of life-
threatening side effects when used as initial therapy,87 transdermal fentanyl systems 
(patches) that deliver analgesia over a 72-hour period remain an important mainstay of 
analgesic therapy for older adults.88 Because of concerns about inappropriate opioid use 
among Medicare beneficiaries,36 Medicare Part D plans may more readily employ 
coverage restrictions or utilization management strategies to reduce opioid use. 
Consequently, during the first year of Medicare Part D, 66% of claims for fentanyl patch 
were not reimbursed because of non-coverage.37 Four years later, utilization management 
requirements and administrative rejections (e.g., inadequate justification for a 
prescription order) accounted for 99% of non-reimbursed claims.13 
The nursing home setting provides a unique context to study the effect of 
Medicare Part D on a vulnerable population – older adults with cancer. As the provision 
of continuing care for older adults has shifted away from the acute care setting, nursing 
homes have become an increasingly essential provider of cancer care for those with 
complex health needs. Among an estimated 1.4 million nursing home residents,4 8.8% 
have a cancer diagnosis that affects their function or treatment.5 One-third of Medicare 
beneficiaries with cancer receive nursing home care during the last 90 days of life, and 
17.1% die in this setting.30 Pain is the most common cancer symptom in older adults and 
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is prevalent in long-term care settings, with up to 29.4% of nursing home residents with 
cancer experiencing pain on a daily basis.6,89 Opioids are the mainstay of cancer pain 
management because of their effectiveness in controlling moderate to severe pain and are 
the most frequently used analgesics in nursing homes.12 We previously found that 
fentanyl accounted for 9.1% of all analgesics prescribed to nursing home residents with 
cancer in 2006 to 2007.89  Fentanyl patches are more expensive than oral opioids of 
similar strength; a single 50 mcg/hr film costs between $14.10 and $22.85.90 Coupled 
with a legal obligation for nursing homes to provide all prescription drugs required by 
residents’ care plans, fentanyl patches may be especially costly for nursing homes to 
provide to residents.91 Medicare Part D coverage restrictions may have further affected 
nursing home residents’ access to fentanyl patches.    
We used a quasi-experimental research design to examine the relationship 
between Medicare Part D implementation and changes in fentanyl patch use among more 
than 18,500 nursing home residents with cancer. Given the safety and cost-related 
concerns surrounding fentanyl patch use, we hypothesized that Medicare Part D led to an 
immediate reduction in use of fentanyl patches. To assess substitution in analgesic 
medication use, we also evaluated concomitant changes in prevalence of other strong 
opioids and less potent opioids.     
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3.2 Methods 
 The institutional review board of the University of Massachusetts Medical School 
approved this study. 
3.2.1 Data Source  
Data were provided by a large long-term care pharmacy and come from more than 
2.5 million unique individuals living in nearly 16,000 nursing homes in 48 states. Data 
include nursing home resident health assessments from the MDS version 2.0 linked with 
an all-payer administrative data source of all dispensed prescription and over-the-counter 
medication.  
3.2.2 Study Sample 
As shown in Figure 3-1, the sampling frame for this study was 234,308 nursing 
home residents with MDS assessments performed between January 1, 2005, and June 30, 
2007. We excluded nursing home residents without a cancer diagnosis indicated on any 
MDS assessment (n = 210,823); residents who were ineligible for Medicare (i.e., <65 
years with no evidence of a Medicare-paid medication) at any point during the study (n = 
1,320); residents missing information on important sociodemographic and clinical 
characteristics (n = 1,183); and residents in facilities that lacked pharmacy dispensing 
records in both pre- and post-Medicare Part D periods (n = 2,383). The final sample size 
was 18,599 nursing home residents with cancer who were admitted to 1,112 facilities 
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nationwide and generated 1,591,067 prescription records from January 2005 through June 
2007. 
3.2.3 Measurement of Analgesic Use 
 Dispensing records were available from January 1, 2005 to June 30, 2007. Data 
elements included all prescription and over-the-counter medication dispensed to nursing 
home residents, dispensing date, product code (NDC), days’ supply, quantity dispensed, 
and payment source. We used a database provided by the long-term care pharmacy to 
translate NDCs into therapeutic classes and subclasses.  
We created four categories of analgesics: 1) all opioids typically used to treat 
moderate to severe pain (WHO level 3 drugs); 2) fentanyl patches; 3) potential fentanyl 
substitutes (other WHO level 3 drugs); and 4) opioids used for mild to moderate pain 
(WHO level 2 drugs). Fentanyl patches included branded and generic medications. Other 
WHO level 3 drugs included oral and injectable formulations of fentanyl, morphine, 
hydromorphone, oxycodone, oxymorphone, methadone, buprenorphine, and 
meperidine.49 Level 2 drugs included codeine, hydrocodone, propoxyphene, pentazocine, 
butorphanol, standardized opium, tramadol, and any combination of these drugs with 
non-steroidal anti-inflammatory drugs and acetaminophen.49 For each of the four 
categories of analgesics, we created two measures: 1) monthly proportion of nursing 
home residents receiving ≥1 prescription of interest and 2) monthly proportion of 
resident-therapy days covered.  
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3.2.4 Statistical Analysis 
 We conducted descriptive analyses comparing nursing home resident 
characteristics and source of payment for fentanyl patch prescriptions prior to and after 
the implementation of Medicare Part D. Previous analyses of the data showed uneven 
capture of payment sources for the first month of the Medicare Part D program (January 
2006),92 so estimates for this month are not reported here. Prescribing rates of all WHO 
level 3 drugs, fentanyl patches, other WHO level 3 drugs, and WHO level 2 drugs were 
graphically examined during each month from January 2005 through December 2005 
(pre-Medicare Part D implementation) and from February 2006 through June 2007 (post-
Medicare Part D implementation). We evaluated the linearity of the relationship between 
prescribing rates and time within each of the two time segments and, based on the visual 
inspection of the prescribing rates, decided to fit a Poisson model, which is appropriate 
for counts of rare events.56 We develop a segmented regression model using a generalized 
linear model approach to estimate the immediate change in the prescribing rate level and 
the gradual change in trend after the implementation of Medicare Part D.55 The basic 
model includes a constant summarizing the baseline level and three terms. The first term 
estimates monthly changes per nursing home resident in the period before Medicare Part 
D implementation, the second estimates the average level change per nursing home 
resident in the first month after Medicare Part D implementation, and the third is the 
trend after Medicare Part D relative to the trend before Medicare Part D implementation. 
The sum of the first and third terms represents monthly changes per resident in the post-
Medicare Part D implementation period. We adjusted this model for underlying time 
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trend (a continuous variable for each month) and rates for January 2006 (a dummy 
variable for this transition month). We also evaluated and ruled out seasonal effect 
(dummy variables for quarters in each calendar year). The impact of Medicare Part D on 
medication use might differ in vulnerable populations. We therefore performed 
sensitivity analyses in the subset of beneficiaries who were dually eligible for Medicare 
and Medicaid (n = 4,266). 
Segmented regression models were fit using Newey-West standard errors to 
account for possible serial correlation of consecutive observations.59 Risk estimates are 
presented as adjusted IRRs and 95% CIs. P≤0.05 (two-tailed) was considered statistically 
significant. All analyses were performed using Stata version 11.2 (StataCorp LP, College 
Station, TX).  
3.3 Results  
A comparison of resident sociodemographic and clinical characteristics before 
and after the January 2006 implementation of Medicare Part D showed few differences 
between nursing home residents in the two time periods (Table 3-1). Explicit terminal 
prognosis was more prevalent prior to the policy change (9.7% pre-implementation vs. 
7.8% post-implementation, P<0.001), as was severe impairment in ADLs (27.0% vs. 
24.6%, P<0.001). However, documented pain was more prevalent after Medicare Part D 
implementation relative to the pre-Medicare Part D period (58.4% vs. 55.9%, P<0.001).  
 
 
66 
 
 
3.3.1 Source of Payment for Fentanyl Patches 
Prior to Medicare Part D, fentanyl patches represented 1.3% (n = 7,302) of all 
dispensed prescriptions and were paid by Medicare Parts A/B (33.3% of prescriptions), 
Medicaid (29.6%), third party insurance (23.1%), facility/hospice (9.3%), and cash 
(4.7%). As in 2005, fentanyl patches represented 1.3% (n = 11.349) of all dispensed 
prescriptions after implementation of Medicare Part. However, Medicare Part D became 
the leading payer of fentanyl patches (46.5%), followed by Medicare Parts A/B (24.9%), 
third party insurance (13.7%), facility/hospice (7.7%), cash (4.8%), and Medicaid (2.3%).  
Similarly, among dual-eligible beneficiaries, fentanyl patches represented 1.3% of 
all dispensed prescriptions in each of the two time periods. In 2005, prescriptions were 
paid by Medicaid (49.6%), third party insurance (25.7%), Medicare Parts A/B (14.8%), 
facility/hospice (7.7%), and cash (2.2%). After February 2006, Medicare Part D became 
the leading payer for fentanyl patch prescriptions (68.5%), followed by third party 
insurance (11.6%), Medicare Parts A/B (7.6%), facility/hospice (6.1%), cash (3.4%), and 
Medicaid (2.9%). 
3.3.2 Effect of the 2006 Implementation of Medicare Part D 
 Figure 3-2 displays the differential effects of Medicare Part D by drug category 
(Panels A-D). Rate of nursing home residents receiving medication (per 1,000 residents) 
is shown in the left column. Rate of therapy days covered (per 1,000 resident-therapy 
days) is shown in the right column. Actual monthly rates are shown as bullet points 
before and after Medicare Part D implementation, which is represented by the dashed 
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vertical line at month 12. Solid lines represent the pre- and post-Medicare Part D slopes, 
while dashed lines represent the expected slope had Medicare Part D not been 
implemented. Table 3-2 provides risk estimates of the effects of Medicare Part D by drug 
category.  
 Prior to Medicare Part D, the monthly rate of medication recipients and monthly 
rate of therapy days covered appeared to increase for all WHO level 3 drugs (Figure 3-
2A), including fentanyl patches (Figure 3-2B) and other WHO level 3 drugs (Figure 3- 
2C), as well as WHO level 2 drugs (Figure 3-2D). The models demonstrate that the rate 
of all WHO level 3 drug receipt increased 2.0% per month, while the rate of therapy days 
covered increased 1.0% per month in 2005. Rate of fentanyl patch receipt also increased 
2.0% per month, but rate of therapy days covered was steeper than that of WHO level 3 
drugs overall: 4.0% per month. While the rate of receipt of other WHO level 3 drugs 
increased 1.0% per month, the monthly rate of therapy days covered was unchanged 
throughout 2005. Similarly, the rate of receipt of WHO level 2 drugs increased 1.0% per 
month, while the rate of therapy days covered was unchanged.     
 In the first month after Medicare Part D implementation, all WHO level 3 drug 
categories experienced marked decreases in rate of medication receipt and rate of therapy 
days covered. Among all WHO level 3 drugs, rate of medication receipt decreased by 
13.0% (95% CI: 11.0–17.0%) and rate of therapy days covered decreased by 26.0% (95% 
CI: 23.0–28.0%). The rate of receipt of fentanyl patches decreased by 10.0% (95% CI: 
7.0–13.0%) and rate of therapy days covered decreased by 22.0% (95% CI: 16.0–28.0%). 
Similarly, the rate of receipt of other WHO level 3 drugs decreased by 21.0% (95% CI: 
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16.0–25.0%) and rate of therapy days covered decreased by 28.0% (95% CI: 22.0–
34.0%). Conversely, there were no statistically significant changes in level of WHO level 
2 drug utilization rates.  
  In the year and a half after Medicare Part D was implemented, the trend in use of 
other WHO level 3 drugs and WHO level 2 drugs approached or surpassed what would 
have been expected had Medicare Part D not been implemented. For all WHO level 3 
drugs, the decreases seen in February 2006 were followed by rates returning to pre-
Medicare Part D levels (increases of 1.0% per month). Although monthly rates of 
fentanyl patch receipt and therapy days covered stabilized, they did not return to the 
increasing monthly rates seen in 2005. The models demonstrate a -2.0% and a -4.0% 
change in the post- versus pre-Medicare Part D slopes for rate of fentanyl patch receipt 
and rate of therapy days covered, respectively. Conversely, utilization rates of other 
WHO level 3 drugs saw increases that were greater in the post- versus pre-Medicare Part 
D periods, with both rates of medication receipt and therapy days covered increasing by 
2.0% per month. Although Medicare Part D had no measureable effect on the rate of 
WHO level 2 drug receipt, the rate of therapy days covered increased 1.0% per month.   
Sensitivity analyses showed the effects of Medicare Part D on opioid use were 
substantively unchanged among the dual-eligible beneficiaries (Table A-4). 
3.4 Discussion 
 Medicare Part D appeared to have had unintended effects on opioid use among 
nursing home residents with cancer who experienced pain. Immediately following 
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implementation of Medicare Part D, there were reductions in the rate of fentanyl patch 
and other strong opioid use among nursing home residents and the rate of therapy days 
covered for all opioids. During the 18 months subsequent to Medicare Part D 
implementation, there were continued decreases in fentanyl patch use. These data support 
the notion that potential substitutions with other strong opioids and less potent opioids 
occurred, and suggest that the impact of Medicare Part D extended beyond the explicitly 
excluded drugs and drug classes.  
 Our findings are consistent with the only other study (to our knowledge) that 
focused on use of long-acting opioids among Medicare Part D beneficiaries. During the 
first year of Medicare Part D, the adjusted risk of >30-day gaps in medication use was 
0.41 among nursing home residents whose Medicare Part D plans did not cover their 
long-acting opioids, versus 0.27 among those with more generous plans (P = 0.0002).86 
However, gaps in medication use did not appear to result in higher rates of 
hospitalizations or deaths among nursing home residents. Neither our study nor previous 
work quantified the impact of these Medicare Part D-induced interruptions on quality of 
nursing home residents’ experiences at the end of life.      
 Generic versions of the fentanyl patch became available in January 2005 and may 
explain the steep monthly increases in medication use through 2005. Despite potential 
increased access to fentanyl patches, we observed interruptions in overall opioid use with 
the introduction of Medicare Part D. Moreover, these observed patterns occurred even 
with multiple checks and balances in place in the nursing home setting to protect 
residents’ receipt of high-quality pain management. For example, the Federal Nursing 
70 
 
 
Home Reform Act (part of the Omnibus Budget Reconciliation Act of 1987), requires 
that nursing homes provide all medications needed to fulfill residents’ care plans.91 
Moreover, CMS began testing pain-focused quality indicators in 199870 and required 
public reporting of the prevalence of uncontrolled pain beginning in 2002.60 Others have 
shown that access to alternate formulations of medications used by nursing home 
residents was affected by limited coverage and frequent use of prior authorization in the 
first year of Medicare Part D.93 It is likely that these findings underestimate the impact 
that Medicare Part D may have had in settings that lack the safeguards present in nursing 
homes.   
 The clinical impact of Medicare Part D on long-term trends in fentanyl patch use 
is unclear. There are concerns about the use of fentanyl patches for initial therapy. Use of 
fentanyl patches for infrequent or mild pain, or for acute pain following surgery, may 
lead to respiratory depression and death.87 Furthermore, increased caution is necessary 
when using fentanyl patches in treating older adults, whose decreased lean body mass 
leads to changes in absorption and increased levels of fentanyl.94 Although our study did 
not evaluate the effect of Medicare Part D policy on nursing home residents’ pain 
experiences, there is evidence that inadequately treated pain has numerous pathological 
consequences, including depression, anxiety, sleep disturbance, decreased socialization, 
and impaired mobility.20–22 Fentanyl patches may be used during opioid rotation to 
attenuate the development of tolerance to other long-acting opioids.68 Its parenteral mode 
of administration could be important for nursing home residents with feeding tubes or 
difficulty swallowing tablets. Moreover, use of sustained-release fentanyl patches instead 
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of shorter-acting oral opioids may simplify otherwise complicated medication regimens, 
which average 8.8 unique medications among older nursing home residents with cancer.89 
Alleviation of pain is an essential component of high-quality care for people who are 
nearing the end of life.95 When used as indicated, fentanyl patches can be part of an 
effective regimen for treating persistent pain among older adults.   
 This study has several strengths. This is the first empirical evaluation of 
Medicare Part D’s impact on opioid use among nursing home residents with cancer. An 
additional strength is our novel use of segmented regression of interrupted time-series 
data to empirically evaluate the effects of a national policy change on opioid use. This 
analytic method is one of the strongest quasi-experimental designs to evaluate the effects 
of time-delimited interventions. Compared to weaker observational study designs, it is 
robust to many of the threats to internal validity,55 including time-invariant confounders 
in the study population and historical changes in fentanyl patch and other opioid use. 
Furthermore, the nationally representative administrative database did not account for 
actual enrollment of nursing home residents into Medicare Part D and spanned a variety 
of payment sources. Therefore, we avoided introduction of selection bias inherent in 
comparisons of medication use between beneficiaries who did and did not enroll in 
Medicare Part D. 
Several limitations should be noted. The segmented regression methods 
aggregated individual-level data by time point. As such, our analysis did not adjust for 
individual-level characteristics. However, pre- and post-Medicare Part D comparisons of 
the study population confirm that resident characteristics did not appreciably vary 
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between the two time periods. Evaluating Medicare Part D’s impact on longer-term 
trends in fentanyl patch and other opioid use was beyond the scope of the data. However, 
we are unaware of similar large-scale drug policies that may have shifted observed opioid 
use patterns among nursing home residents with cancer in the years since Medicare Part 
D was first implemented. The pharmacy dispensing records available did not permit us to 
evaluate the clinical appropriateness of drugs prescribed. Lastly, our analyses included 
Medicare-eligible nursing home residents with cancer whose prescriptions were filled by 
a single long-term care pharmacy. Caution should be taken when generalizing the 
findings to the larger population of nursing home residents with cancer. 
 3.5 Conclusion 
Intended and unintended effects should be carefully measured before—and 
continually reassessed in the years after—large-scale health policies are implemented. 
This quasi-experimental study demonstrated that the January 2006 implementation of 
Medicare Part D led to immediate and continued reductions in receipt of fentanyl patches 
among nursing home residents with cancer. These medication use patterns occurred 
despite secular trends that may have otherwise increased access to fentanyl patches and 
pain management safeguards in the nursing home setting. The clinical impact of these 
interruptions is uncertain, and it was beyond the scope of this study to quantify the impact 
of Medicare Part D on quality of life among nursing home residents with cancer. In light 
of these patients’ residence in a medically supervised setting and consequent low 
potential for medication abuse, expansion of Medicare Part D’s coverage of pain 
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medication and alternative opioid formulations should be considered for this 
vulnerable population.  
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Table 3-1: Characteristics of Nursing Home Residents with Cancer, Pre- and Post-
Medicare Part D Implementation  
 
 
Pre-Medicare Part D 
(Jan 2005–Dec 2005)  
n = 10,392 
Post-Medicare Part D  
(Feb 2006–Jun 2007)  
n = 12,999 
Age   
     <65  4.2 5.2 
     65–74 17.7 17.9 
     75–84 41.9 40.2 
     ≥85 36.2 36.7 
Women 57.0 56.4 
Race and ethnicity    
     Non-Hispanic white 84.6 83.3 
     Non-Hispanic black 10.7 11.2 
     Hispanic 3.3 3.8 
     Asian or Pacific Islander 1.2 1.6 
     American Indian or Alaskan  
     Native 
0.2 0.2 
Widowed 49.4 47.7 
Source of admissionb   
     Acute care hospital 80.3 81.6 
     Private home 8.1 7.8 
     Other nursing home 6.5 5.9 
     Otherc 5.0 4.8 
US census region   
     South  30.8 31.3 
     West  14.6 17.2 
     Midwest  35.3 32.7 
     Northeast  19.3 18.8 
Degree of functional impairmentd   
     Moderate 44.7 47.5 
     Severe 27.0 24.6 
Degree of cognitive impairmente   
     Moderate 48.9 46.8 
     Severe 8.3 6.8 
Depressed moodf 10.9 10.1 
Bedfast 4.8 3.8 
Terminal prognosisg 9.7 7.8 
Number of diagnoses 6.6 ± 2.7 (1–20) 6.4 ± 2.6 (1–19) 
Clinical conditions   
     Arthritis 29.0 26.7 
     Osteoporosis 15.9 14.6 
     Hip fracture 5.7 6.1 
Number of unique medications 3.4 ± 2.4 (1–12) 3.9 ± 3.0 (1–16) 
Painh 55.9 58.4 
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Pre-Medicare Part D 
(Jan 2005–Dec 2005)  
n = 10,392 
Post-Medicare Part D  
(Feb 2006–Jun 2007)  
n = 12,999 
     Daily 23.4 24.2 
     Less than daily 32.5 34.1 
 
Nresidents = 18,599 (4,792 nursing home residents were observed in both periods) 
Nfacilities = 1,112 
Percentage and mean ± standard deviation (range) shown.  
a 5,093 missing information on source of admission.  
b Includes board and care/assisted living/group home, psychiatric hospital, rehabilitation hospital. 
c Based on a 7-level scale: Activities of Daily Living Hierarchy Scale score of 3 or 4 for moderate 
impairment, 5 or 6 for severe impairment.41  
d Based on a 7-level scale: Cognitive Performance Scale scores of 2 to 4 for moderate 
impairment, 5 or 6 for severe impairment.43 
e Based on a scale from 0–14: Depression Rating Scale scores ≥3 indicate major or minor 
depressive disorders.42 
f Indicated by prognosis of <6 months or receipt of hospice. 
g As assessed by nursing home staff over a 7-day period. 
 
 
 
77 
Figure 3-2. Impact of Medicare Part D on Rate of Opioid Receipt and Rate of Therapy Days Covered in Nursing Home 
Residents with Cancer, Jan 2005–Jun 2007 
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Figure 3-2, Continued. Impact of Medicare Part D on Rate of Opioid Receipt and Rate of Therapy Days Covered in 
Nursing Home Residents with Cancer, Jan 2005–Jun 2007 
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Table 3-2: Impact of Medicare Part D on A) Rate of Opioid Receipt and B) Rate of Opioid Therapy Days Covered in 
Nursing Home Residents with Cancer, Jan 2005–Jun 2007 
A. Rate of opioid receipt   
 
 WHO level 3 drugs WHO level 2 drugs 
 All Fentanyl patch Other WHO level 3 drugs 
 
 
 
 
IRRa 
 
 
95% CI 
 
 
IRRa 
 
 
95% CI 
 
 
IRRa 
 
 
95% CI 
 
 
IRRa 
 
 
95% CI 
 
Pre-Part D Slope   1.02 1.01–1.02 1.02 1.02–1.03 1.01 1.01–1.02 1.01 1.00–1.02 
Post-Part D Slope  1.01 1.01–1.01 1.00 1.00–1.01 1.02 1.01–1.02 1.01 1.00–1.01 
Change in rate in 
February 2006 
0.87 0.83–0.89 0.90 0.87–0.93 0.79 0.75–0.84 1.02 0.95–1.09 
Change in slope 
(after vs before Part 
D) 
1.00 0.99–1.00 0.98 0.97–0.99 1.01 1.00–1.01 0.99 0.99–1.00 
 
B.  Rate of opioid therapy days covered 
 
 WHO level 3 drugs WHO level 2 drugs 
 All Fentanyl patch Other WHO level 3 drugs 
 
 
 
 
IRRa 
 
 
95% CI 
 
 
IRRa 
 
 
95% CI 
 
 
IRRa 
 
 
95% CI 
 
 
IRRa 
 
 
95% CI 
 
Pre-Part D Slope   1.01 1.01–1.01 1.04 1.03–1.05 0.99 0.99–1.00 1.00 0.99–1.01 
Post-Part D Slope  1.01 1.01–1.02 1.00 0.99–1.01 1.02 1.02–1.03 1.01 1.01–1.01 
Change in rate in 
February 2006 
0.74 0.72–0.77 0.78 0.72–0.84 0.72 0.66–0.78 0.97 0.90–1.04 
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 WHO level 3 drugs WHO level 2 drugs 
 All Fentanyl patch Other WHO level 3 drugs 
 
 
 
 
IRRa 
 
 
95% CI 
 
 
IRRa 
 
 
95% CI 
 
 
IRRa 
 
 
95% CI 
 
 
IRRa 
 
 
95% CI 
 
Change in slope 
(after vs before Part 
D) 
1.00 1.00–1.01 0.96 0.95–0.97 1.03 1.02–1.04 1.01 1.00–1.02 
 
CI: confidence interval; IRR: incidence rate ratio 
a Adjusted for serial correlation using Newey-West standard errors 
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CHAPTER IV:  
NAÏVE INITIATION OF LONG-ACTING OPIOIDS IN NURSING HOME 
RESIDENTS  
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ABSTRACT 
BACKGROUND: Despite known risks of overdose and respiratory depression when treating 
opioid-naïve individuals with long-acting opioids, use of these potent agents may be common in 
nursing homes. Our objective was to estimate the prevalence of naïve initiation of long-acting 
opioids since national efforts to increase prescriber and public awareness on the safe use of these 
potent medications.  
METHODS: This cross-sectional study included 9,543 Medicare-enrolled, long-stay nursing 
home residents in 3,018 US nursing homes. The MDS 3.0 linked with Medicare enrollment, 
hospital claims, and prescription drug transaction data (January-December 2011) were used to 
determine the prevalence of naïve initiation among nursing home residents who initiated a long-
acting opioid in the nursing home. Binomial logistic regression was used to evaluate resident-
level correlates of naïve-initiation of a long-acting opioid.  
RESULTS: Of nursing home residents who initiated a long-acting opioid within 30 days of a 
nursing home admission, 10.0% (95% CI: 9.4–10.6%) had not used an opioid in the previous 60 
days. Naïve initiation of long-acting opioids was positively associated with life expectancy <6 
months (adjusted OR = 1.96, 95% CI: 1.58–2.43), moderate/severe functional impairment 
(adjusted OR = 1.32, 95% CI: 1.12–1.55), feeding tubes (adjusted OR = 1.53, 95% CI: 1.15–
2.04), and a cancer diagnosis (adjusted OR = 1.39, 95% CI: 1.16–1.67). 
CONCLUSION: Naïve initiation of long-acting opioids persists in nursing homes, especially 
among residents who may require alternative opioid formulations or who are at the end of life. 
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4.1 Introduction 
Opioid analgesics are essential treatment options for people who suffer from 
moderate to severe pain. In nursing homes—medically supervised settings that have 
frequent use of medications for end-of-life care31—use of these potent agents is common. 
In Chapter II, we reported that among nursing home residents with a diagnosis of 
cancer, an estimated 36% of those with daily severe pain, and 21% of persons with daily 
moderate pain, received a long-acting opioid during the first week of a nursing home 
stay.89 Despite their useful role in pain management, risks of opioid use in nursing home 
residents should not be minimized. In the nursing home setting, opioids were among the 
top five drugs associated with overall adverse drug events and preventable adverse drug 
events.96  
The FDA requires that “boxed” warnings appear on the labels or package inserts 
of long-acting opioids to call attention to their use in opioid-tolerant patients only. Long-
acting opioids are potent drugs with prolonged time to elimination. Improper use of long-
acting opioids is associated with substantial health risks, such as fatal overdose because 
of respiratory depression among patients not already tolerant to high doses of opioids. In 
July 2005 and December 2007, the FDA issued public health advisory warnings to alert 
health care providers, patients, and caregivers on the safe use of transdermal fentanyl 
systems (patches).87,97 The only study (to our knowledge) to estimate the prevalence of 
naïve initiation of long-acting opioids in the nursing home setting used Rhode Island 
Medicaid data from 2004 and 2005.32 In this study, 39.3% of nursing home residents who 
received a long-acting opioid had not used any opioid in the previous 60 days.32 Whether 
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the prevalence of naïve initiation of long-acting opioid use in nursing homes has declined 
since the FDA advisories is unknown.  
An update to our current understanding of the prescribing of long-acting opioids 
to opioid-naïve nursing home residents is needed. FDA safety communications have 
reduced the use of antipsychotics in older adults with dementia,98 long-acting β-agonists 
in patients with asthma,99 antidepressants in young adults with new-onset depression,100 
and rosiglitazone for the treatment of type 2 diabetes.101–103 We hypothesized that the 
prevalence of naïve initiation would have declined in light of efforts to increase 
prescriber and public awareness on the safe use of long-acting opioids. Therefore, we 
used recent national data of Medicare beneficiaries to estimate the prevalence, and to 
identify correlates, of naïve-initiation of long-acting opioids in nursing homes.   
4.2 Methods  
 The institutional review board of the University of Massachusetts Medical School 
approved this study. 
4.2.1 Data Sources 
We used four data sources: 1) MDS version 3.0, 2) Master Beneficiary Summary 
Files that determine Medicare enrollment, 3) MedPar files containing hospital claims 
data, and 4) Medicare Part D prescription drug transaction data. 
MDS 3.0 is a systematic and comprehensive assessment of care planning and 
resident health that consists of sociodemographic information; clinical items (e.g., falls 
and balance items, bladder and bowel, communication, behavior, signs, symptoms); 
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active diagnoses; and treatments, procedures, and  programs.44,45 Nursing home providers 
are required to perform full assessments on residents at the time of nursing home 
admission and annually thereafter ;a subset of the MDS items are assessed quarterly or 
when a resident experiences a significant change in health status.44  
MDS 3.0 is a revision of MDS 2.0 (used from 1999 to 2010) and was 
implemented in all Medicare- and Medicaid-certified nursing homes in October 2010. It 
is widely accepted for research purposes and, compared with  earlier versions of the 
resident assessment instrument, offers improved quality and completeness of some data 
constructs, including symptoms and psycho-social experiences.104 The most significant 
conceptual departure from MDS 2.0 is the inclusion of direct resident interviews to assess 
key domains of health. Although resident interviews are the preferred method for 
completing the assessment, nursing home staff may answer alternative observation items 
on behalf of residents who cannot make themselves understood at least some of the time 
or who cannot complete an interview. Family members or significant others may answer 
items regarding resident preferences.  
4.2.2 Study Sample 
 As shown in Figure 4-1, the sample frame for this study was 3,273,636 Medicare-
enrolled nursing home residents with an admission assessment performed between 
January 1, 2011, and December 31, 2011. We required that residents have a nursing home 
stay 90 days (n = 1,103,195), as Medicare Part D prescription drug transaction data may 
not include medications associated with skilled nursing facility care covered by Medicare 
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Part A. We excluded residents who were admitted to the nursing home between January 
1, 2011, and March 31, 2011 (n = 130,598) because we were unable to observe 90 days 
of their medication use prior to nursing home admission. We also excluded residents who 
were comatose (n = 3,479); who did not initiate a long-acting opioid after nursing home 
admission (n = 949,965); who did not have three months of continuous enrollment in 
Medicare Part D prior to initiation of a long-acting opioid in the nursing home (n = 
1,176); who had a hospital admission in the seven days prior to initiation of a long-acting 
opioid in the nursing home (n = 874); or who were missing information on key 
sociodemographic or clinical characteristics (n = 1,041). We identified a total of 16,062 
nursing home residents who met these eligibility criteria. Although we estimated the 
proportion of residents naively initiating a long-acting opioid using several subsamples 
derived from this sample, the primary analysis was conducted in 9,543 residents admitted 
to 3,018 facilities who initiated a long-acting opioid in the first 30 days of nursing home 
admission. 
4.2.3 Measurement of Opioid Use and Opioid Tolerance  
 We used Medicare Part D prescription drug transactions from January 1, 2011, to 
December 31, 2011. Data elements included brand and generic names of all prescription 
drugs dispensed to nursing home residents, product identification code (NDC), service 
date, days’ supply, quantity dispensed, drug strength, and drug formulation. 
The Multum drug database was used to code drug names and to map those names to 
therapeutic categories.  
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 The primary outcome of interest was naïve initiation of a long-acting opioid 
within the first 30 days of a nursing home admission. We categorized opioid analgesics 
by duration of effect (i.e., long-acting, short-acting) according to recent clinical practice 
guidelines that consider pain management by level of opioid-tolerance.10,50,51 Long-acting 
opioids included controlled- or extended-release formulations of hydromorphone, 
morphine sulfate, oxycodone, oxymorphone, and tramadol, as well as any dose of a 
fentanyl or buprenorphine patch. Short-acting opioids included immediate-release 
formulations of buprenorphine, butorphanol, codeine, fentanyl, hydrocodone, 
hydromorphone, meperidine, morphine sulfate, nalbuphine, opium, oxymorphone, 
oxycodone, pentazocine, tapentadol, and tramadol. Opioids combined with 
acetaminophen or non-steroidal anti-inflammatory drugs, which limit the maximum daily 
dose because of risks of liver and gastrointestinal toxicity, were also considered as short-
acting agents.52 CMS quality indicators include the prevalence of uncontrolled moderate-
to-severe pain occurring within the first 14 days of nursing home admission.105 We 
evaluated the first 30 days of a nursing home stay based on the expectation that initial 
provision of analgesic medications would occur shortly after admission.  
 To facilitate comparison with published estimates of naïve-initiation of long-
acting opioids in nursing home residents,32 individuals were considered opioid-naïve if 
they had not used a short- or a long-acting opioid in the 60 days preceding initial receipt 
of a long-acting opioid after a nursing home admission. Since some states limit 
prescriptions of controlled substances to a 30-day supply,106 we expected a 60-day look 
back period to capture intermittent use of opioid analgesics. We also evaluated initiation 
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of long-acting opioids within different time periods after nursing home admission (7 days 
[n = 5,298]; 14 days [n = 6,507]; 60 days [n = 12,381]; 90 days [n = 13,782]; and anytime 
[n = 16,062]). 
4.2.4 Measurement of Correlates 
 Correlates were selected based on previous evidence of association with naïve 
initiation of long-acting opioids32 and were drawn from MDS admission assessments. 
Key sociodemographic characteristics included age, sex, and race/ethnicity. Clinical 
characteristics included source of nursing home admission (acute hospital, community, 
other); life expectancy of 6 months at nursing home admission; need for parenteral 
feeding or feeding tube; difficulty chewing; difficulty swallowing; resident rejection of 
care “necessary to achieve the resident’s goals for health and well-being”;44 active 
diagnoses that may impact analgesic treatment; functional status; cognitive status; and 
pain. Functional status was based on the Resource Utilization Groups-III ADL scale, with 
scores ranging from 4 (no impairment) to 18 (severe impairment).46 Cognitive status was 
based on the Cognitive Function Scale, with residents categorized as cognitively intact, 
mildly impaired, moderately impaired, or severely impaired.47 Section J of the MDS 3.0 
defined pain as “pain or hurting at any time” during the five days preceding the 
assessment.44 One item addressed pain frequency (rarely/occasionally, frequently/almost 
constantly). Per guidance by Edelen and Saliba,63 we combined responses from the 
numeric rating and verbal descriptor scales to characterize pain intensity (mild, moderate, 
severe/very severe).63 
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4.2.5 Statistical Analysis 
 First, we estimated the proportion of residents with naïve initiation of long-acting 
opioids by varying the look back period (30 days, 60 days, or 90 days) and the time since 
nursing home admission (7 days, 14 days, 30 days, 60 days, 90 days, or anytime). We 
performed these sensitivity analyses to facilitate comparisons with previous work.32 
Second, using the sample for the primary outcome of interest (i.e., naïve initiation within 
the first 30 days of nursing home admission, with a 60 day look back period), we 
described resident-level characteristics by source of nursing home admission (i.e., acute 
setting, community, other). With the sample size available, trivial differences in the 
distributions achieved statistical significance. As such, absolute differences in 
percentages of 5% were considered noteworthy. 
 We developed a binary logistic model to estimate associations among resident-
level correlates and naïve initiation of long-acting opioids. Before constructing the 
model, we calculated correlations among variables. No variable pairs were highly 
collinear (>0.90); therefore, we included all correlates of interest in the model. The 
logistic model was fit using robust estimation of standard errors to account for correlation 
between residents within the same nursing home.69 Unadjusted and adjusted ORs and 
95% CIs were derived from the models.  
In a sensitivity analysis, we separately evaluated residents with a cancer diagnosis 
(n = 1,660), as long-acting opioids are accepted treatment options for cancer-related 
pain.10,50,51 Cancer was indicated in MDS Section I “Active Diagnoses” through a check 
box or ICD-9-CM codes 140.XX–203.XX. We also performed sensitivity analyses where 
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we: 1) evaluated initiation of a long-acting opioid anytime after a nursing home 
admission and 2) varied the definition of opioid-naiveté to non-receipt of an opioid in the 
previous 90 days before long-acting opioid initiation. All analyses were performed using 
Stata version 11.2 (StataCorp LP, College Station, TX).  
4.3 Results 
 Figure 4-2 shows estimates of naïve long-acting opioid initiation using different 
look back periods and at different times since nursing home admission. Of all residents 
who received a long-acting opioid in the nursing home, nearly 30.0% initiated within the 
first week of admission and 59.4% within the first 30 days. The proportion with naïve 
initiation of long-acting opioids was 13.9–27.5% using a 30-day look back period, 9.7–
18.6% using a 60-day look back period, and 6.6–11.8% using a 90-day window. 
Regardless of look back period, estimates of naïve initiation were similar within 30 days 
of admission (e.g., 9.7% in those initiating a long-acting opioid in the first 7 days and 
10.0% in the first 30 days of admission). Of residents who initiated a long-acting opioid 
within 30 days of admission, 10.0% (95% CI: 9.4–10.6%) had not used an opioid 
analgesic in the previous 60 days. 
 The majority (58.3%) of residents were admitted to the nursing home from an 
acute hospital (Table 4-1). Residents had a mean age of 75.0  13.3 years, 72.2% were 
female, and 86.4% were non-Hispanic white. Nearly 71.2% of residents had moderate to 
severe functional impairment and 21.6% had moderate to severe cognitive impairment. 
Overall, 86.9% had pain documented, among whom 31.5% had moderate or severe pain 
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and 73.4% had frequent or almost constant pain. Compared to their counterparts admitted 
from the community or other non-acute setting, those admitted from an acute hospital 
were younger and more likely to have hip fracture, stroke, and documented pain. 
However, they were less likely to have cognitive impairment, Alzheimer disease, 
arthritis, osteoporosis, and a terminal prognosis. Among residents with documented pain 
(86.9%), those admitted from an acute care setting were more likely than residents from a 
non-acute setting to have experienced pain constantly during the five days prior to 
assessment; however, that pain was more likely to be mild. 
 Women and nursing home residents with arthritis or stroke had decreased odds of 
naively initiating a long-acting opioid (Table 4-2). Compared with residents admitted to 
the nursing home from a community setting, residents from another non-acute setting or 
an acute hospital were more likely to have naively initiated a long-acting opioid. 
Similarly, nursing home residents with a terminal prognosis, functional impairment, 
feeding tubes, and cancer were more likely to have naively initiated a long-acting opioid.  
  Among nursing home residents with cancer (n = 1,660), naïve long-acting opioid 
initiation was positively associated with terminal prognosis, functional impairment, and 
hip fracture (Table A-5). The sensitivity analyses in which we evaluated long-acting 
opioid initiation anytime after nursing home admission (Table A-6) and extended the 
look back period to 90 days (Table A-7) were generally consistent with results found in 
the primary analysis. However, the former analysis found an increased likelihood of 
naïve initiation in residents with pulmonary conditions and decreased likelihood in 
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residents with osteoporosis. In the latter analysis, we did not find statistically significant 
associations of naïve initiation among women or residents with a feeding tube or stroke.  
4.4 Discussion 
This study demonstrates that 10% of nursing home residents who received a long-
acting opioid in the first month of nursing home admission had not previously been on 
opioid therapy. These results are significantly decreased from those documented before 
large-scale changes to analgesic medication use in the nursing home setting. Residents 
with functional impairments, feeding tubes, cancer, or terminal prognosis at nursing 
home admission had increased odds of naively initiating a long-acting opioid.  
Dosa and colleagues estimated that approximately 39.3% of nursing home 
residents who received a long-acting opioid in the nursing home had not previously been 
on opioid therapy.32 However, our estimates of naïve initiation using varied definitions of 
opioid naivety fell below this estimate (Figure 4-2); indeed, when we used similar 
parameters (i.e., 60-day look back and initiation of a long-acting opioid anytime after 
nursing home admission), 18.6% of nursing home residents who received a long-acting 
opioid were opioid-naïve. Our results may differ from earlier estimates because of the 
previous study’s small sample size, focus on nursing homes residents in one state (Rhode 
Island), and use of data that predated national changes to medication use in the nursing 
home setting and campaigns to increase awareness around safe opioid analgesic use.     
We anticipated changes in the provision of long-acting opioids since the mid-
2000s for several reasons. In March 2009, CMS revised surveyors’ interpretative 
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guidelines for meeting compliance in the evaluation and management of pain in nursing 
home residents (F-Tag 309). Lapane and colleagues showed that these revisions 
improved nursing home providers’ recognition and management of pain, and also 
increased use of opioid analgesics among nursing home residents with documented non-
cancer pain.107 Moreover, we demonstrated in Chapter III that the January 2006 
implementation of the Medicare Part D prescription drug benefit may have impacted use 
of opioids in the nursing home setting. Specifically, Medicare Part D led to sustained 
reductions in the use of fentanyl patches and potential substitution of these long-acting 
opioids with other strong opioids and less potent opioids to treat residents with cancer. 
Both the FDA and clinical guidelines for pain management in older adults 
strongly advise against the use of long-acting opioids to treat patients who are not already 
tolerant to high doses of opioid therapy.87,68,97 Serious adverse effects associated with 
improper use of long-acting opioids include respiratory depression and unintentional 
overdose. However, there are some individuals whose clinical needs require adjustments 
to the recommended course of stepped therapy. We found evidence of increased naïve 
initiation of long-acting opioids among nursing home residents with functional 
impairment and feeding tubes, who may be unable to tolerate oral formulations or 
frequent dosing of short-acting analgesics. Residents with cancer and terminal prognosis 
were also more likely to have naively initiated a long-acting opioid. The need to 
effectively control moderate-to-severe pain and provide patient comfort at the end of life 
may outweigh the risk of potential adverse drug effects. This is consistent with studies 
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that have found increased polypharmacy–especially with medication for symptom 
control108,109–after referral to palliative care.108–111  
The landscape of opioid prescribing in long-term care continues to change. In July 
2012, the FDA approved a class-wide Risk Evaluation and Mitigation Strategy (REMS) 
for long-acting opioids. The purpose of the REMS is to, “reduce serious adverse 
outcomes resulting from inappropriate prescribing, misuse, and abuse of extended-release 
or long-acting opioid analgesics while maintaining access to pain medications.”112 
Through the REMS, the FDA requires pharmaceutical companies and distributors to 
provide education for medication prescribers and resources for counseling patients about 
the risks and benefits of long-acting opioid use. Failure to comply with these strategies 
may result in financial penalties of up to $10 million, and a long-acting opioid may be 
deemed to be misbranded.113 Future research is needed to evaluate the extent to which 
these dramatic changes in medication safety strategies actually reach health care 
providers in nursing homes and, consequently, impact the quality of opioid therapy in this 
setting.     
The present study has several strengths worth highlighting. First, we used national 
data from CMS to provide new evidence on long-acting opioid use in a large, national 
sample of Medicare beneficiaries residing in nursing homes. Second, we used nursing 
home residents assessments from the MDS 3.0, which emphasizes direct resident 
interviews and thus offers improved quality and completeness of information on 
symptoms and other subjective constructs.104 Third, our use of Medicare Part D 
prescription drug transactions allowed for evaluations of opioid use before and after 
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nursing home admission. Finally, we included in our study sample nursing home 
residents who received any extended- or controlled-release opioid analgesic. Previous 
work evaluated only those who initiated a fentanyl patch, long-acting oxycodone, or 
long-acting morphine sulfate.     
There were also some limitations. Due to our reliance on prescription drug 
transactions from a single payer, there is potential misclassification of nursing home 
residents as opioid-naïve. For example, we expected that residents admitted from an acute 
hospital would be less likely than their community-based counterparts to experience 
naïve long-acting opioid initiation, yet we demonstrated the opposite relationship. The 
lack of all-payer drug dispensing records may, therefore, have resulted in an 
overestimation of the proportion of nursing home residents who naively initiated a long-
acting opioid. Moreover, our definition of naïve-tolerance is very liberal; we considered a 
nursing home resident to be opioid-tolerant if they used any dose of opioid analgesic 
prior to initiating a long-acting opioid.     
4.5 Conclusion 
 This study provides a timely update to what is known about potentially 
inappropriate use of long-acting opioids in nursing home residents. Recent efforts to 
improve the quality of medication use and to increase awareness around the safe use of 
opioid analgesics may have had a positive effect on pain management in nursing homes. 
However, special attention should continue to be paid to nursing home residents who 
require alternative opioid formulations or who are at the end of life. Educational efforts 
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that target medication prescribers should also consider the important roles that non-
prescribers (e.g., direct-care nursing staff) play in the provision of high-quality pain 
management for nursing home residents.  
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Table 4-1: Characteristics of Nursing Home Residents who Initiated a Long-Acting Opioid, by Source of Admission  
 Acute hospital 
(n = 5,563) 
Communitya 
(n = 2,252)  
Otherb 
(n = 1,728) 
Age, years    
     65  22.8 13.5 19.7 
     65–74 26.5 16.3 22.1 
     75–84 29.3 30.8 29.6 
     85 21.4 39.4 28.7 
Women 71.5 76.1 69.7 
Race and ethnicity    
     Non-Hispanic white 83.1 92.7 89.0 
     Non-Hispanic black 10.0 4.3 6.9 
     Hispanic  4.9 1.9 2.9 
     Asian  1.2 0.4 0.7 
     American Indian or  
          Alaskan Native 
0.4 0.5 0.4 
     Native Hawaiian or  
          Other Pacific Islander 
0.2 0.3 0.1 
     Multiracial 0.1 0.0 0.2 
Life expectancy of <6 months 6.7 11.2 8.9 
Degree of functional  
     impairmentc 
   
     Moderate 47.1 37.4 36.6 
     Severe 29.0 22.3 33.7 
Degree of cognitive impairmentd    
     Moderate 8.9 15.3 17.3 
     Severe 9.1 8.6 12.7 
Parenteral feeding or feeding  
     tube 
5.4 1.5 4.1 
Difficulty chewing 2.0 2.2 2.7 
Difficulty swallowing 5.0 4.7 5.8 
Clinical conditions    
     Cancer 17.8 19.1 14.0 
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 Acute hospital 
(n = 5,563) 
Communitya 
(n = 2,252)  
Otherb 
(n = 1,728) 
     Arthritis 34.2 43.3 38.7 
     Osteoporosis 17.2 23.0 19.9 
     Hip fracture 5.6 0.8 2.9 
     Asthma, chronic obstructive  
     pulmonary disease, or   
     chronic lung disease  
29.8 27.0 31.8 
     Respiratory failure 2.8 0.5 1.2 
     Heart failure 17.3 19.1 22.3 
     Alzheimer disease 2.6 7.1 8.0 
     Stroke 7.6 9.2 13.3 
Rejected care 8.4 10.7 13.3 
Pain at admissione 90.3 83.4 80.5 
Pain frequency, if pain presentf    
     Rarely/occasionally  24.9 27.5 31.1 
     Frequently/almost constantly  75.1 72.5 68.9 
Pain severity, if pain presentf    
     Mild 70.7 64.1 67.7 
     Moderate 15.5 19.9 18.7 
     Severe/very severe 13.9 16.0 13.6 
 
N = 9,543 
Percentages presented. 
a Includes private home/apartment, board/care, assisted living, and group home. 
b Includes other nursing home, psychiatric hospital, inpatient rehabilitation facility, mental retardation/developmental disabilities facility, 
hospice, and other. 
c Based on scores from 4 to 18: Resource Utilization Groups-III Activities of Daily Living score of 14 to 16 for moderate impairment, 17 
or 18 for severe impairment.46 
d Based on 4-level Cognitive Function Scale.47    
e As assessed by resident interview or nursing home staff observation over a 5-day period. 
f Residents were missing information on pain frequency (n = 92) and pain severity (n = 200). 
  
 
 
 
  
101 
Table 4-2: Correlates of Naive Long-Acting Opioid Initiation in Newly Admitted Nursing Home Residents 
  
Naïve initiation 
(n = 951) 
 
Non-naïve initiation 
(n = 8,592) 
Likelihood of naïve initiation 
Unadjusted OR  
(95% CI) 
Adjusteda OR  
(95% CI) 
Source of admission     
     Acute hospital 63.8 57.7 1.66 (1.37–2.00) 1.53 (1.26–1.85) 
     Communityb 16.3 24.4 Referent Referent 
     Otherc 19.9 17.9 1.66 (1.32–2.09) 1.62 (1.28–2.04) 
Age, years      
     65  21.6 19.9 1.00 (0.82–1.22) 1.04 (0.85–1.28) 
     65–74 25.0 23.1 Referent Referent 
     75–84 31.2 29.5 0.98 (0.81–1.17) 1.08 (0.90–1.31) 
     85 22.2 27.5 0.75 (0.62–0.90) 0.90 (0.74–1.12) 
Women 65.6 73.0 0.71 (0.61–0.81) 0.80 (0.69–0.93) 
Race and ethnicity     
     Non-Hispanic white 84.1 86.7 Referent Referent 
     Non-Hispanic black 10.1 7.8 1.33 (1.06–1.66) 1.12 (0.89–1.42) 
     Hispanic  3.5 3.9 0.92 (0.63–1.34) 0.81(0.55–1.20) 
     Otherd 2.3 1.6 1.49 (0.96–2.32) 1.30 (0.81–2.09) 
Life expectancy of <6 months 15.9 7.3 2.39 (1.99–2.87) 1.96 (1.58–2.43) 
Moderate/severe functional  
     impairmente 
76.7 70.5 1.37 (1.18–1.60) 1.32 (1.12–1.55) 
Moderate/severe cognitive 
     impairmentf 
24.9 21.2 1.23 (1.06–1.44) 1.13 (0.95–1.36) 
Parenteral feeding or feeding tube 7.3 3.9 1.92 (1.48–2.50) 1.53 (1.15–2.04) 
Difficulty chewing 2.1 2.2 0.96 (0.60–1.53) 0.90 (0.56–1.43) 
Difficulty swallowing 5.6 5.0 1.12 (0.84–1.49) 0.92 (0.67–1.25) 
Clinical conditions     
     Cancer 25.7 16.5 1.75 (1.49–2.05) 1.39 (1.16–1.67) 
     Arthritis 29.9 37.9 0.70 (0.60–0.80) 0.82 (0.70–0.95) 
     Osteoporosis 14.6 19.5 0.71 (0.59–0.85) 0.88 (0.72–1.06) 
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Naïve initiation 
(n = 951) 
 
Non-naïve initiation 
(n = 8,592) 
Likelihood of naïve initiation 
Unadjusted OR  
(95% CI) 
Adjusteda OR  
(95% CI) 
     Hip fracture 4.7 3.9 1.23 (0.90–1.68) 1.16 (0.84–1.61) 
     Asthma, chronic obstructive  
     pulmonary disease, or chronic  
     lung disease  
32.9 29.1 1.19 (1.03–1.38) 1.16 (1.00–1.35) 
     Respiratory failure 3.2 1.9 1.72 (1.15–2.56) 1.25 (0.82–1.90) 
     Heart failure 19.9 18.5 1.09 (0.92–1.30) 1.12 (0.94–1.33) 
     Alzheimer disease 3.8 4.7 0.80 (0.57–1.12) 0.95 (0.66–1.36) 
     Stroke 7.5 9.2 0.80 (0.62–1.02) 0.76 (0.59–0.98) 
Rejected care 8.7 9.9 0.87 (0.68–1.10) 0.80 (0.62–1.03) 
 
N = 9,543 
Percentages presented. 
CI: confidence interval; OR: odds ratio 
a Adjusted for all variables listed in Table 4-1. 
b Includes private home/apartment, board/care, assisted living, and group home. 
c Includes other nursing home, psychiatric hospital, inpatient rehabilitation facility, mental retardation/developmental disabilities facility, 
hospice, and other. 
d Includes Asian, Native Hawaiian/Pacific Islander, Native American/Alaska Native, and  multiracial. 
e Based on scores from 4 to 18: Resource Utilization Groups-III Activities of Daily Living score of 14 to 16 for moderate impairment, 17 
or 18 for severe impairment.46  
f Based on 4-level Cognitive Function Scale.47   
g As assessed by reside  nt interview or nursing home staff observation over a 5-day period. 
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 In this dissertation, we 1) examined the quality of pain management among 
cancer patients residing in nursing homes (Chapter II); 2) explored the immediate and 
short-term impacts of the Medicare Part D prescription drug benefit on access to opioid 
analgesia among this population (Chapter III); and 3) examined the use of more potent 
opioid formulations five years after the implementation of Medicare Part D (Chapter 
IV).    
5.1 Chapter II: Pain Management in Nursing Home Residents with Cancer 
In Chapter II, we examined the use of analgesics among more than 8,000 cancer 
patients residing in US nursing homes in 2006 and 2007. Specifically, we estimated the 
prevalence and resident-level correlates of pain and receipt of analgesics among newly-
admitted older and disabled nursing home residents with cancer. 
We found that the majority (65.6%) of nursing home residents with a cancer 
diagnosis experience pain. A substantial proportion of that pain is daily, and moderate to 
severe in intensity. Between 2006 and 2007, 17.6% of nursing home residents whose pain 
occurred on a daily basis failed to receive treatment with analgesic medications in the 
first week of nursing home admission. These results are only modestly decreased from 
estimates published in 1998, prior to national efforts to improve the quality of pain 
management in nursing homes.   
This study contributes a much-needed update to what is known about the quality 
of pain management in nursing home residents with cancer, a critical public health issue 
of increasing prominence. Pain remains common and undertreated among some of the 
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most vulnerable cancer patients in the US, and special attention should be paid to the 
oldest old, those with cognitive impairment, and residents of potentially poor quality 
nursing homes. Among nursing home residents overall, recent national goals for 
prevalence of moderate-to-severe pain were 15% for short-stay, post-acute residents and 
4% for long-stay residents.49 Although cancer-specific targets for pain management do 
not currently exist, these data suggest that the current state of pain management among 
nursing home residents with cancer falls short of these goals. New information provided 
in this dissertation may provide initial directions for targeted efforts to improve the 
quality of pain treatment in nursing homes, including redoubled efforts to disseminate 
older adult-specific clinical practice guidelines in this setting. 
5.2 Chapter III: Should Opioid Pain Medications Receive Special Medicare Part 
D Coverage Protection for Nursing Home Residents with Cancer?  
In Chapter III, we examined the relationship between the implementation of 
Medicare Part D and changes in fentanyl patch use among more than 18,500 nursing 
home residents with cancer. Given the safety and cost-related concerns surrounding the 
use of this potent opioid analgesic, we hypothesized that Medicare Part D led to an 
immediate reduction in use of fentanyl patches. To assess potential substitution, we also 
evaluated concomitant changes in use of similarly strong oral opioid formulations and use 
of less potent opioids.     
We found that Medicare Part D may have had unintended effects on opioid use 
among nursing home residents with cancer who experienced pain. Immediately following 
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implementation of Medicare Part D, there were reductions in the prevalence rates of 
fentanyl patch and other strong opioid use and the rates of therapy days covered for all 
opioids. During the 18 months subsequent to Medicare Part D implementation, there were 
continued decreases in fentanyl patch use. These data support the notion that potential 
substitutions with other strong opioids and less potent opioids occurred, and suggest that 
the impact of Medicare Part D extended beyond the drugs and drug classes that the 
Medicare program explicitly excludes from coverage.   
This study highlights the need for careful measurement and continual assessment 
of both intended and unintended effects of large-scale health policies. The immediate and 
continued reductions in use of fentanyl patches among nursing home residents with 
cancer occurred despite secular trends that may have otherwise increased access to these 
medications and pain management safeguards in the nursing home setting. The clinical 
impact of these interruptions is uncertain, and it was beyond the scope of this study to 
quantify the impact of Medicare Part D on quality of life among nursing home residents 
with cancer. In light of these patients’ residence in a medically supervised setting and 
consequent low potential for medication abuse, expansion of Medicare Part D’s coverage 
of pain medication and alternative opioid formulations should be considered for this 
vulnerable population. 
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5.3 Chapter IV: Naïve Initiation of Long-Acting Opioids in Nursing Home 
Residents 
In light of evidence of interruptions in medication use patterns immediately 
following the implementation of Medicare Part D, we examined in Chapter IV the 
current use of long-acting opioid analgesia in the nursing home setting. Specifically, we 
estimated the prevalence and identified correlates of naïve-initiation of long-acting 
opioids among a general population of more than 9,000 Medicare beneficiaries residing 
in US nursing homes in 2011.  
Despite known health risks associated with use of long-acting opioids to treat 
opioid-naïve individuals, we found that 10.0% of nursing home residents who received a 
long-acting opioid in the first month of a nursing home stay were not already tolerant to 
opioid analgesics. Individual-level factors associated with increased odds of naïve 
initiation of a long-acting opioid included a cancer diagnosis, terminal prognosis, 
functional impairment, and use of a feeding tube. Although such care is not concordant 
with clinical practice guidelines and FDA guidance on stepped therapy approaches, these 
results are significantly decreased from estimates obtained prior to large-scale changes to 
analgesic medication use in the nursing home setting and national efforts to heighten 
prescriber, patient, and caregiver awareness of safe long-acting opioid use.   
5.4 Future Directions 
Despite the presence of clinical practice guidelines for pain management of older 
adults and, more specifically, adults with cancer, this dissertation demonstrates the need 
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to improve the quality of pain management in the nursing home setting. Re-doubled 
efforts are needed to disseminate these clinical practice guidelines, improve their uptake 
and adoption in the long-term care setting, and make necessary adjustments to more 
appropriately meet the specialized needs of patients within this context.   
Improvements are continually being made to the instruments that assess the 
medical needs of nursing home residents and the quality of their care. The replacement of 
MDS 2.0 with MDS 3.0 allows for greater input from the nursing home resident; 
therefore, future research should include re-evaluations of the prevalence of pain among 
nursing home residents with cancer.  
In addition, prescription drug policies that are evolving at the national level may 
have great impact on patterns to medication use in the long-term care setting. These 
changes include tightening or easing of Medicare Part D formulary requirements, the 
number of private drug plans that participate in the prescription drug program, and the 
ways in which utilization requirements are employed. Moreover, the July 2012 approval 
of the FDA’s class-wide REMS for extended-release and long-acting opioids may greatly 
improve education of health care providers and patients on appropriate prescribing and 
safe use of these potent medications. Given the challenges associated with 
implementation of clinical practice guidelines for pain management in nursing homes, the 
extent to which changes in medication safety strategies reach healthcare providers in this 
setting should be examined. Therefore, there is a critical need for continual evaluations of 
the landscape of opioid prescribing in the nursing home setting.   
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SUPPLEMENTARY TABLES FOR CHAPTER II: PAIN MANAGEMENT IN NURSING HOME RESIDENTS 
WITH CANCER 
Table A-1: Correlates of Pain in Older Nursing Home Residents with Cancer and Admission from a Hospital 
 Pain frequency 
Daily pain vs. 
no pain (referent) 
< Daily pain vs. 
no pain (referent) 
  
Daily 
n = 2,216  
 
 
< Daily 
n = 2,538 
 
 
None 
n = 1,856 
 
Unadjusted  
OR  
(95% CI) 
Adjusteda  
OR  
(95% CI) 
Unadjusted  
OR   
(95% CI) 
Adjusteda  
OR  
(95% CI) 
Age, years        
     65–74 18.4 22.3 28.8 Referent Referent Referent Referent 
     75–84 45.3 45.7 45.9 0.65 (0.55–0.76) 0.68 (0.58–0.80) 0.83 (0.72–0.96) 0.84 (0.73–0.97) 
     ≥85 36.4 32.0 25.3 0.44 (0.37–0.53) 0.47 (0.39–0.57) 0.73 (0.62–0.85) 0.73 (0.61–0.87) 
Women 45.9 54.3 59.3 1.72 (1.51–1.96) 1.66 (1.44–1.93) 1.40 (1.25–1.57) 1.36 (1.19–1.54) 
Race and ethnicity         
     Non-Hispanic  
     white 
81.3 84.1 84.8 Referent Referent Referent Referent 
     Non-Hispanic  
     black 
12.3 9.7 9.5 0.75 (0.61–0.91) 0.76 (0.62–0.94) 0.77 (0.62–0.95) 0.80 (0.64–1.00) 
     Otherb  6.4 6.2 5.7 0.86 (0.66–1.11) 0.92 (0.70–1.20) 0.93 (0.72–1.21) 0.99 (0.76–1.28) 
Widowed 43.9 46.4 44.7 1.03 (0.91–1.17) 1.00 (0.86–1.16) 1.11 (0.99–1.24) 1.06 (0.93–1.20) 
Functional  
     impairmentc 
74.8 76.0 77.5 1.16 (0.99–1.36) 1.29 (1.09–1.53) 1.07 (0.92–1.23) 1.12 (0.96–1.30) 
Cognitive   
     impairmentd 
50.8 43.5 36.5 0.56 (0.49–0.64) 0.71 (0.61–0.82) 0.75 (0.66–0.84) 0.84 (0.73–0.97) 
Depressed moode 5.3 6.5 11.0 2.22 (1.73–2.83) 2.18 (1.68–2.82) 1.26 (0.97–1.63) 1.21 (0.93–1.56) 
Feeding tubes 7.4 7.7 5.1 0.67 (0.52–0.87) 0.70 (0.53–0.92) 1.05 (0.84–1.30) 1.11 (0.89–1.40) 
Indwelling catheter 21.2 25.5 28.6 1.49 (1.29–1.72) 1.50 (1.29–1.75) 1.27 (1.12–1.46) 1.28 (1.11–1.47) 
Use of restraintsf 2.5 1.7 0.8 0.31 (0.18–0.55) 0.47 (0.26–0.85) 0.65 (0.44–0.96) 0.82 (0.55–1.23) 
Bedfast 3.0 4.3 6.5 2.22 (1.61–3.06) 2.14 (1.52–3.01) 1.45 (1.05–2.01) 1.48 (1.05–2.07) 
Terminal prognosisg 4.6 5.7 9.1 2.08 (1.59–2.70) 2.00 (1.50–2.67) 1.26 (0.97–1.63) 1.27 (0.97–1.67) 
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N = 6,610 
CI: confidence interval; OR: odds ratio 
a Adjusted for all listed variables and variables describing participation in MDS assessment (resident, family, significant other) and 
communication skills.    
b Includes Hispanic, Asian or Pacific Islander, and American Indian or Alaskan Native.  
c Activities of Daily Living Hierarchy Scale scores equal 3 or more.41  
d Cognitive Performance Scale scores equal 2 or more.43  
e Depression Rating Scale scores equal 3 or more. 
f Includes trunk and limb restraints as well as chairs to prevent rising. 
g Indicated by prognosis of <6 months or receipt of hospice.
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Table A-2: Correlates of Receiving Any Analgesic in Older Nursing Home Residents 
with Cancer, Admission from a Hospital, and Any Pain 
 
 
Any analgesic 
n = 3,188 
 
No analgesic 
n = 1,206 
Likelihood of receiving any 
analgesic for any pain 
Unadjusted 
OR  
(95% CI) 
Adjusteda 
OR  
(95% CI) 
Age, years     
     65–74 26.8 20.6 Referent Referent 
     75–84 46.6 43.6 0.82 (0.68–0.98) 0.88 (0.73–1.07) 
     >85  26.6 35.8 0.57 (0.47–0.69) 0.67 (0.54–0.82) 
Women 57.3 54.0 1.14 (0.99–1.32) 1.17 (1.00–1.37) 
Race and ethnicity      
     Non-Hispanic  
     White 
84.9 83.0 Referent Referent 
     Non-Hispanic  
     black 
9.3 10.6 0.86 (0.69–1.06) 0.93 (0.74–1.17) 
     Otherb 5.8 6.4 0.89 (0.69–1.16) 0.89 (0.67–1.18) 
# other medication 
     in first week 
    
     <5 24.8 44.1 Referent Referent 
     6–10 40.7 33.6 2.15 (1.81–2.55) 2.33 (1.95–2.77) 
     >11 34.4 22.3 2.74 (2.27–3.32) 3.02 (2.46–3.70) 
Functional   
     impairmentc 
76.6 76.9 0.98 (0.83–1.16) 1.14 (0.95–1.36) 
Cognitive   
     impairmentd 
37.1 49.8 0.59 (0.52–0.68) 0.68 (0.58–0.81) 
Depressed moode 8.7 7.6 1.16 (0.89–1.50) 1.14 (0.87–1.50) 
Feeding tubes 6.1 8.0 0.74 (0.58–0.94) 0.69 (0.53–0.90) 
Use of restraintsf 0.9 2.3 0.39 (0.24–0.63) 0.48 (0.29–0.80) 
Bedfast 5.4 4.7 1.16 (0.84–1.60) 1.17 (0.84–1.63) 
Terminal   
     prognosisg 
7.8 5.6 1.43 (1.07–1.90) 1.66 (1.23–2.23) 
 
N = 4,394 
Percentages presented. 
CI: confidence interval; OR: odds ratio 
a Adjusted for all variables listed in Table A-1and variables describing participation in MDS 
assessment (family, significant other) and communication skills. 
b Includes Hispanic, Asian or Pacific Islander, or American Indian or Alaskan Native. 
c Activities of Daily Living Hierarchy Scale scores equal 3 or more.41  
d Cognitive Performance Scale scores equal 2 or more.43  
e Depression Rating Scale scores equal 3 or more.42 
f Includes trunk and limb restraints as well as chairs to prevent rising. 
g Indicated by prognosis of <6 months or receipt of hospice. 
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Table A-3: Correlates of Receiving Opioid Analgesia in Newly Admitted Nursing 
Home Residents with Cancer and Moderate/Severe Pain  
  
Opioid 
analgesic 
n = 970 
 
No opioid 
analgesic 
n = 3,003 
Likelihood of receiving an opioid 
for moderate/severe pain 
Unadjusted 
OR  
(95% CI) 
Adjusteda 
OR  
(95% CI) 
Age, years     
     <65  7.3 4.2 1.30 (0.90–1.89) 1.23 (0.84–1.82) 
     65–74 25.6 19.3 Referent Referent 
     75–84 43.3 42.8 0.76 (0.63–0.93) 0.83 (0.68–1.01) 
     >85  23.8 33.7 0.53 (0.43 –0.65) 0.64 (0.51–0.80) 
Women 57.8 57.6 1.01 (0.87–1.16) 1.03 (0.87–1.21) 
Race and ethnicity      
     Non-Hispanic  
     white 
83.9 82.7 Referent Referent 
     Non-Hispanic  
     black 
10.0 10.8 0.91 (0.72–1.15) 0.88 (0.68–1.14) 
     Otherb 6.1 6.5 0.93 (0.69–1.25) 0.77 (0.56–1.06) 
Admitted from      
     acute hospital 
89.5 85.2 1.49 (1.21–1.85) 1.42 (1.13–1.79) 
# other medication  
     in first week 
    
     <5 25.5 46.2 Referent Referent 
     6–10 40.5 30.9 2.46 (2.07–2.93) 2.70 (2.25–3.23) 
     >11 34.0 22.9 2.79 (2.31–3.36) 3.08 (2.51–3.79) 
Functional   
     impairmentc 
75.9 76.8 0.95 (0.81–1.13) 1.09 (0.90–1.32) 
Cognitive  
     impairmentd 
35.6 47.7 0.61 (0.52–0.70) 0.67 (0.56–0.80) 
Depressed moode 10.7 10.2 1.05 (0.83–1.33) 1.16 (0.90–1.49) 
Feeding tubes 6.1 7.3 0.82 (0.62–1.09)  0.71 (0.52–0.97) 
Use of restraintsf 0.9 1.6 0.60 (0.32–1.13) 0.72 (0.38–1.36) 
Bedfast 6.5 5.7 1.16 (0.85–1.57) 1.21 (0.86–1.69) 
Terminal prognosisg 10.9 9.7 1.13 (0.89–1.45) 1.46 (1.11–1.91) 
 
N = 3,973 
Percentages presented. 
CI: confidence interval; OR: odds ratio 
a Adjusted for all variables listed in Table A-1 and variables describing participation in Minimum 
Data Set assessment (family, significant other) and communication skills. 
b Includes Hispanic, Asian or Pacific Islander, or American Indian or Alaskan Native. 
c Activities of Daily Living Hierarchy Scale scores equal 3 or more.41  
d Cognitive Performance Scale scores equal 2 or more.43  
e Depression Rating Scale scores equal 3 or more.42 
f Includes trunk and limb restraints as well as chairs to prevent rising. 
g Indicated by prognosis of <6 months or receipt of hospice
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APPENDICES FOR CHAPTER III: SHOULD OPIOID PAIN MEDICATIONS RECEIVE SPECIAL MEDICARE 
PART D COVERAGE PROTECTION FOR NURSING HOME RESIDENTS WITH CANCER? 
Table A-4: Impact of Medicare Part D on Rate of Opioid Receipt in Dual-Eligible Nursing Home Residents with 
Cancer, Jan 2005–Jun 2007 
 
 WHO level 3 drugs WHO level 2 drugs 
 All Fentanyl patch Other WHO level 3 drugs 
 
 
 
 
IRRa 
 
 
95% CI 
 
 
IRRa 
 
 
95% CI 
 
 
IRRa 
 
 
95% CI 
 
 
IRRa 
 
 
95% CI 
 
Pre-Part D Slope   1.01 1.01–1.02 1.03 1.02–1.03 1.01 1.00–1.01 1.03 1.02–1.04 
Post-Part D Slope  1.01 1.01–1.01 1.01 1.01–1.02 1.01 1.00–1.01 1.01 1.00–1.02 
Change in rate in 
February 2006 
0.89 0.86–0.92 0.88 0.83–0.93 0.90 0.84–0.96 1.03 0.95–1.13 
Change in slope 
(after vs before Part 
D) 
1.00 0.99–1.00 0.99 0.98–1.00 1.00 0.99–1.01 0.98 0.97–1.00 
 
N = 4,266 
CI: confidence interval; IRR: incidence rate ratio 
a Adjusted for serial correlation using Newey-West standard errors  
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APPENDICES FOR CHAPTER IV: NAÏVE INITIATION OF LONG-ACTING OPIOIDS IN NURSING HOME 
RESIDENTS 
Table A-5: Correlates of Naive Long-Acting Opioid Initiation in Nursing Home Residents with Cancer  
  
Naïve initiation 
(n = 244) 
 
Non-naïve initiation 
(n = 1,416 ) 
Likelihood of naïve initiation 
Unadjusted OR (95% 
CI) 
Adjusteda OR (95% CI) 
Source of admission     
     Acute hospital 56.2 60.2 0.92  (0.66–1.27) 0.85 (0.60–1.20) 
     Communityb 26.2 25.8 Referent Referent 
     Otherc 17.6 14.1 1.23 (0.79–1.93) 1.23 (0.78–1.94) 
Age, years     
     65  15.6 14.8 1.12  (0.72–1.74) 1.17(0.75–1.82) 
     65–74 28.3 30.1 Referent Referent 
     75–84 36.1 32.1 1.19  (0.85–1.67) 1.21 (0.86–1.71) 
     85 20.1 23.0 0.93  (0.63–1.37) 0.94 (0.61–1.44) 
Women 61.9 63.4 0.94  (0.71–1.25) 1.00 (0.74–1.34) 
Race and ethnicity     
     Non-Hispanic white 83.2 82.6 Referent Referent 
     Non-Hispanic black 10.7 10.6 1.00  (0.63–1.58) 0.97 (0.61–1.56) 
     Hispanic or Latino 4.1 4.3 0.94  (0.47–1.89) 0.88 (0.43–1.80) 
     Otherd 2.1 2.5 0.80  (0.31–2.07) 0.80 (0.29–2.23) 
Life expectancy of <6 months 36.9 24.9 1.77  (1.33–2.35) 1.66 (1.23–2.24) 
Moderate/severe functional   
     impairmente 
75.0 67.6 1.44  (1.07–1.94) 1.45 (1.06–1.99) 
Moderate/severe cognitive 
    impairmentf 
52.1 46.5 1.26  (0.94–1.70) 1.14(0.81–1.59) 
Parenteral feeding or feeding tube 7.4 5.6 1.35  (0.80–2.27) 1.49 (0.86–2.59) 
Difficulty chewing 3.3 2.9 1.14  (0.53–2.46) 1.09 (0.50–2.37) 
Difficulty swallowing 7.0 8.3 0.82  (0.48–1.40) 0.76 (0.43–1.32) 
Clinical conditions     
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Naïve initiation 
(n = 244) 
 
Non-naïve initiation 
(n = 1,416 ) 
Likelihood of naïve initiation 
Unadjusted OR (95% 
CI) 
Adjusteda OR (95% CI) 
     Arthritis 20.5 26.3 0.72  (0.52–1.00) 0.78 (0.55–1.10) 
     Osteoporosis 6.6 11.9 0.52  (0.30–0.88) 0.54 (0.31–0.94) 
     Hip fracture 6.2 3.4 1.87  (1.03–3.38) 2.07 (1.12–3.82) 
     Asthma, chronic obstructive  
     pulmonary disease, or chronic  
     lung disease 
27.5 29.8 0.89  (0.66–1.20) 0.95 (0.70–1.29) 
     Respiratory failure 1.2 1.3 0.92  (0.27–3.09) 0.80 (0.22–2.92) 
     Heart failure 13.9 14.1 0.99  (0.67–1.47) 1.09 (0.73–1.64) 
     Alzheimer disease 2.9 2.2 1.32  (0.57–3.04) 1.64 (0.67–4.06) 
     Stroke 4.5 6.6 0.66  (0.35–1.26) 0.70 (0.37–1.35) 
Rejected care 9.0 10.2 0.88  (0.54–1.41) 0.76 (0.45–1.27) 
 
N = 1,660 
Percentages presented. 
CI: confidence interval; OR: odds ratio 
a Adjusted for all listed variables. 
b Includes private home/apartment, board/care, assisted living, and group home. 
c Includes other nursing home, psychiatric hospital, inpatient rehabilitation facility, mental retardation/developmental disabilities facility, 
hospice, and other. 
d Includes Asian, Native Hawaiian/Pacific Islander, Native American/Alaska Native, and multiracial. 
e Based on scores from 4 to 18: Resource Utilization Groups-III Activities of Daily Living score of 14 to 16 for moderate impairment, 17 
or 18 for severe impairment.46  
f Based on 4-level Cognitive Function Scale.47 
g As assessed by resident interview or nursing home staff observation over a 5-day period.  
    
117 
Table A-6: Correlates of Naive Long-Acting Opioid Initiation Anytime After Nursing Home Admission 
  
Naïve initiation 
(n = 1,262) 
 
Non-naïve initiation 
(n = 8,281) 
Likelihood of naïve initiation 
Unadjusted OR  
(95% CI) 
Adjusteda OR  
(95% CI) 
Source of admission     
     Acute hospital 60.4 58.0 1.33 (1.13–1.56) 1.23 (1.04–1.45) 
     Communityb 19.0 24.3 Referent Referent 
     Otherc 20.6 17.7 1.48 (1.22–1.80) 1.44 (1.18–1.75) 
Age, years      
     65  21.9 19.8 1.09 (0.91–1.30) 1.12 (0.93–1.34) 
     65–74 23.6 23.3 Referent Referent 
     75–84 31.2 29.4 1.05 (0.89–1.23) 1.15 (0.97–1.36) 
     85 23.3 27.5 0.83 (0.70–0.99) 1.00 (0.83–1.20) 
Women 66.6 73.1 0.73 (0.65–0.83) 0.81 (0.71–0.92) 
Race and ethnicity     
     Non-Hispanic white 85.3 86.6 Referent Referent 
     Non-Hispanic black 9.4 7.9 1.22 (0.99–1.50) 1.07 (0.87–1.33) 
     Hispanic or Latino 3.3 3.9 0.86 (0.61–1.20) 0.80 (0.57–1.13) 
     Otherd 1.9 1.6 1.18 (0.77–1.81) 1.08 (0.69–1.69) 
Life expectancy of <6 months 13.1 7.4 1.87 (1.57–2.23) 1.57 (1.28–1.92) 
Moderate/severe functional   
     impairmente 
74.8 70.6 1.24 (1.08–1.42) 1.24 (1.07–1.43) 
Moderate/severe cognitive  
     impairmentf 
23.1 21.4 1.10 (0.96–1.27) 1.06 (0.90–1.24) 
Parenteral feeding or feeding tube 6.3 3.9 1.63 (1.27–2.09) 1.37 (1.05–1.79) 
Difficulty chewing 2.5 2.1 1.15 (0.79–1.69) 1.10 (0.75–1.62) 
Difficulty swallowing 5.3 5.0 1.06 (0.81–1.38) 0.90 (0.68–1.20) 
Key diagnoses     
     Cancer 23.4 16.5 1.55 (1.34–1.79) 1.33 (1.13–1.57) 
     Arthritis 32.5 37.9 0.79 (0.70–0.90) 0.89 (0.79–1.02) 
     Osteoporosis 14.8 19.7 0.71 (0.60–0.84) 0.83 (0.69–0.98) 
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Naïve initiation 
(n = 1,262) 
 
Non-naïve initiation 
(n = 8,281) 
Likelihood of naïve initiation 
Unadjusted OR  
(95% CI) 
Adjusteda OR  
(95% CI) 
     Hip fracture 4.4 3.9 1.14 (0.85–1.54) 1.14 (0.85–1.54) 
     Asthma, chronic obstructive  
     pulmonary disease, or chronic    
     lung disease 
33.5 28.9 1.24 (1.09–1.41) 1.20 (1.06–1.37) 
     Respiratory failure 3.0 1.8 1.66 (1.16–2.38) 1.30 (0.89–1.90) 
     Heart failure 20.1 18.4 1.11 (0.95–1.29) 1.10 (0.95–1.29) 
     Alzheimer disease 3.6 4.8 0.74 (0.54–1.00) 0.83 (0.60–1.15) 
     Stroke 8.3 9.1 0.90 (0.73–1.12) 0.87 (0.70–1.08) 
Rejected care 8.9 10.0 0.88 (0.72–1.09) 0.84 (0.67–1.04) 
 
N = 9,543 
Percentages presented. 
CI: confidence interval; OR: odds ratio 
a Adjusted for all listed variables. 
b Includes private home/apartment, board/care, assisted living, and group home. 
c Includes other nursing home, psychiatric hospital, inpatient rehabilitation facility, mental retardation/developmental disabilities facility, 
hospice, and other. 
d Includes Asian, Native Hawaiian/Pacific Islander, Native American/Alaska Native, and multiracial. 
e Based on scores from 4 to 18: Resource Utilization Groups-III Activities of Daily Living score of 14 to 16 for moderate impairment, 17 
or 18 for severe impairment.46  
f Based on 4-level Cognitive Function Scale.47  
g As assessed by resident interview or nursing home staff observation over a 5-day period.  
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Table A-7: Correlates of Naive Long-Acting Opioid Initiation (90-Day Look Back Period) 
  
Naïve initiation 
(n = 602) 
 
Non-naïve initiation 
(n = 8,941) 
Likelihood of naïve initiation 
Unadjusted OR  
(95% CI) 
Adjusteda OR  
(95% CI) 
Source of admission     
     Acute hospital 58.5 58.3 1.29 (1.03–1.61) 1.26 (1.00–1.58) 
     Communityb 18.6 23.9 Referent Referent 
     Otherc 22.9 17.8 1.66 (1.26–2.18) 1.68 (1.27–2.22) 
Age      
     65  19.3 20.1 0.98 (0.76–1.26) 1.03 (0.80–1.34) 
     65–74 22.9 23.3 Referent Referent 
     75–84 32.9 29.5 1.14 (0.91–1.42) 1.22 (0.97–1.53) 
     85 24.9 27.1 0.94 (0.74–1.19) 1.07 (0.83–1.37) 
Women 67.6 72.6 0.79 (0.66–0.94) 0.86 (0.71–1.03) 
Race and ethnicity     
     Non-Hispanic white 85.2 86.5 Referent Referent 
     Non-Hispanic black 10.0 7.9 1.27 (0.96–1.68) 1.17 (0.88–1.57) 
     Hispanic or Latino 3.0 3.9 0.78 (0.47–1.27) 0.72 (0.43–1.20) 
     Otherd 1.8 1.7 1.12 (0.61–2.06) 1.01 (0.53–1.91) 
Life expectancy of <6 months 18.6 7.5 2.83 (2.29–3.50) 2.30 (1.81–2.93) 
Moderate/severe functional  
     impairmente 
77.6 70.7 1.43 (1.18–1.74) 1.39 (1.13–1.70) 
Moderate/severe cognitive  
     impairmentf 
26.4 21.3 1.33 (1.11–1.60) 1.15 (0.93–1.42) 
Parenteral feeding or feeding tube 5.7 4.2 1.38 (0.97–1.98) 1.16 (0.78–1.70) 
Difficulty chewing 1.8 2.2 0.83 (0.45–1.52) 0.75 (0.40–1.41) 
Difficulty swallowing 5.7 5.0 1.13 (0.79–1.61) 0.94 (0.65–1.36) 
Key diagnoses     
     Cancer 26.4 16.8 1.78 (1.46–2.16) 1.36 (1.10–1.70) 
     Arthritis 29.7 37.6 0.70 (0.58–0.84) 0.78 (0.65–0.95) 
     Osteoporosis 15.5 19.3 0.77 (0.61–0.96) 0.91 (0.72–1.15) 
     Hip fracture 4.3 4.0 1.10 (0.73–1.64) 1.06 (0.70–1.59) 
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Naïve initiation 
(n = 602) 
 
Non-naïve initiation 
(n = 8,941) 
Likelihood of naïve initiation 
Unadjusted OR  
(95% CI) 
Adjusteda OR  
(95% CI) 
     Asthma, chronic obstructive  
     pulmonary disease, or chronic  
     lung disease 
31.6 29.4 1.11 (0.93–1.33) 1.10 (0.91–1.33) 
     Respiratory failure 2.5 2.0 1.28 (0.75–2.18) 1.11 (0.64–1.95) 
     Heart failure 20.3 18.5 1.12 (0.90–1.38) 1.11 (0.89–1.38) 
     Alzheimer disease 3.8 4.7 0.81 (0.53–1.24) 0.85 (0.55–1.32) 
     Stroke 7.8 9.1 0.85 (0.63–1.14) 0.81 (0.60–1.10) 
Rejected care 8.5 9.9 0.84 (0.62–1.14) 0.76 (0.55–1.04) 
 
N = 9,543 
Percentages presented. 
CI: confidence interval; OR: odds ratio 
a Adjusted for all listed variables. 
b Includes private home/apartment, board/care, assisted living, and group home. 
c Includes other nursing home, psychiatric hospital, inpatient rehabilitation facility, mental retardation/developmental disabilities facility, hospice, other. 
d Includes Asian, Native Hawaiian/Pacific Islander, Native American/Alaska Native, and multiracial. 
e Based on scores from 4 to 18: Resource Utilization Groups-III Activities of Daily Living score of 14 to 16 for moderate impairment, 17 or 18 for 
severe impairment.46  
f Based on 4-level Cognitive Function Scale.47 
g As assessed by resident interview or nursing home staff observation over a 5-day period. 
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